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Tumour-derived Organoid Cultures model  1 
Primary Human Liver Cancer in vitro 2 
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Abstract  27 
Human liver cancer research currently lacks in vitro models that faithfully recapitulate the 28 
pathophysiology of the original tumour. We recently described a novel, near-physiological 29 
organoid culture system, where primary human healthy liver cells form long-term expanding 30 
organoids that retain liver tissue function and genetic stability. Here, we extend this culture 31 
system to the propagation of primary liver cancer (PLC) organoids from three of the most 32 
common PLC subtypes: hepatocellular carcinoma (HCC), cholangiocarcinoma (CC) and 33 
combined HCC/CC (CHC) tumours. PLC-derived organoid cultures preserve the histological 34 
architecture, gene expression and genomic landscape of the original tumour, allowing 35 
discrimination between different tumour tissues and subtypes, even after long term expansion 36 
in culture in the same medium conditions. Xenograft studies demonstrate that the 37 
tumourogenic potential, histological features and metastatic property of PLC-derived 38 
organoids are preserved in vivo. Furthermore, PLC-derived organoids prove useful in 39 
identifying novel genes involved in liver cancer progression, such as C1QBP (for CC) and 40 
C19orf48 (for HCC), and are amenable for drug screening, thus facilitating the identification 41 
of the ERK inhibitor SCH772984 as a potential therapeutic agent for liver cancer. We thus 42 
demonstrate the wide-ranging biomedical utilities of PLC-derived organoid models in 43 
furthering the understanding of liver cancer biology and in developing drug screening 44 
platforms for liver cancer personalized medicine approaches.  45 
 2
Primary liver cancer (PLC) represents a major health problem [1]. It is the second most 46 
common malignancy worldwide in terms of mortality, and incidence rates are rising, mainly 47 
due to an increase in associated risk factors such as diabetes and obesity [2, 3]. Primary liver 48 
cancer is generally classified into either hepatocellular carcinoma (HCC) or 49 
cholangiocarcinoma (CC), with the majority of all primary liver tumours falling into one of 50 
these two categories [1]. Also, a combined hepatocellular-cholangiocarcinoma (CHC), 51 
accounting for 0.4 to 14.2% of all PLCs [4] harbours intermediate characteristics between 52 
HCC and CC [5]. Albeit both, HCC and CC are easily distinguishable by their histological 53 
appearance [3, 5] and genetic and transcriptional landscapes [6], with CHC sharing 54 
histological features of both [7], PLC is overall a complex entity, which renders each case of 55 
the disease unique and in need of precise and personalized treatment approaches.  56 
 57 
The development of effective treatments for liver cancer has been hindered by the shortage of 58 
reproducible human models to assess the efficacy of candidate therapeutic agents [8]. 59 
Historically, preclinical models have mainly consisted of genetically engineered mouse 60 
models or of human tumour-derived cell lines propagated in either 2D-culture or as 61 
xenografts in mice [8-10]. While 2D-culture has allowed pioneering advances in cancer cell 62 
and molecular biology, it fails to recapitulate critical features of a growing tumour in vivo 63 
[11]. These include the 3D organization of cells as well as cell-cell and cell-matrix 64 
interactions within the tumour. In addition, PLC, especially CCs, have proven difficult to 65 
propagate in vitro, with only 2 cell lines reported thus far [12, 13].  66 
 67 
There has been recent emergence of in vitro culture systems of primary, non-transformed 68 
tissues growing as 3D structures, termed organoids, which accurately recapitulate tissue 69 
architecture and function. Organoids have opened up avenues to study human physiology and 70 
disease in an unprecedented manner [14]. Thus retinal, cerebral, kidney, intestinal and 71 
stomach organoids (among others) have already been generated from pluripotent stem cells 72 
for the study of human development and disease ex vivo [15]. In addition, organoids are 73 
promising disease models not only for understanding the biology of human diseases but also 74 
for testing drug efficacy in vitro, before moving to animal models. Notably, however, the 75 
study of human cancer, a disease of adult somatic cells, requires the establishment of culture 76 
systems directly from patient material as opposed to pluripotent stem cells. Accordingly, 77 
mouse and human cancer organoids have recently been established for colon [16-18], 78 
pancreas [16, 19] and prostate [20] tumours, but not, thus far, from liver tumours. 79 
 80 
Based on our previous work in mouse liver and pancreas organoid cultures [21, 22], we 81 
recently showed that organoid cultures derived from human liver donor/healthy biopsies 82 
could be expanded long-term in vitro while preserving their liver functionality and genetic 83 
stability over time [23]. Here, we demonstrate the proof-of-concept that liver organoid 84 
cultures also recapitulate human primary liver cancer in vitro. Hence, we have successfully 85 
established organoid cultures from 8 PLC patients, encompassing three of the most common 86 
subtypes of primary liver cancer [1]: HCC, CC and CHC. PLC-derived organoids recapitulate 87 
the histological architecture, expression profile, genomic landscape and in vivo 88 
tumourigenesis of the parent tumour, even after long-term expansion in culture. In addition, 89 
we demonstrate the utility of PLC-derived organoids for identifying novel genes potentially 90 
involved in liver cancer progression and potential novel therapeutic targets, thus opening up 91 
opportunities for drug testing and advances in personalized medicine approaches. 92 
 93 
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RESULTS 94 
 95 
Tumour-derived human primary liver cancer organoids expand long-term in vitro while 96 
preserving the histological architecture and marker expression of the specific tumour 97 
subtype they derive from. 98 
 99 
By adapting our previous protocol to isolate and expand murine adult liver stem/progenitor 100 
cells [22], we have recently established culture conditions for the long-term expansion of 101 
human cells derived from liver donor/healthy biopsies [23, 24]. Here, we sought to selectively 102 
expand tumour cells from human PLC tissue by optimizing our established human liver 103 
expansion protocol. Surgically resected liver tumour tissue was obtained from untreated PLC 104 
patients who had no history of viral-meditated hepatitis (excluded under Institutional safety 105 
guidelines). The specimens were assessed for routine histological diagnostic and staging 106 
requirements prior to tissue being taken for organoid derivation, part of this tissue also being 107 
retained and preserved for genomic, transcriptomic and histological analyses. The remainder 108 
was dissociated and processed for culturing (Fig. 1a). We observed that normal/healthy 109 
contaminating tissue within the samples gave rise to organoids that would quickly outcompete 110 
the tumour-derived organoids, presumably due to differences in genetic stability, as 111 
previously reported for colon cancer [18]. Therefore, to avoid the growth of healthy 112 
contaminating organoids, we modified our derivation protocol by (i) adapting the timing of 113 
tissue digestion, (ii) changing the starting culture conditions using, in addition of the classical 114 
isolation medium for healthy liver-derived organoid culture [23, 24], a newly defined PLC-115 
derived organoids isolation medium consisting in the classical expansion medium for healthy 116 
liver-derived organoids [23, 24] without Rspo1 and supplemented with 3nM Dexamethasone 117 
and Y27632 (Fig. 1c) and (iii) closely monitoring the developing organoid structures (see 118 
Suppl. Fig. 1 + methods for details). 119 
Using this novel protocol, we successfully established human PLC-derived organoids from 8 120 
different PLC patients, including poorly to moderate-to-well differentiated HCC (n=3) and 121 
CC (n=3), and combined HCC/CC (CHC; n=2) (Fig. 1, Suppl. Fig. 2a and Suppl. Table 1). 122 
We found a strong correlation between the derivation success rate (establishment) and the 123 
proliferation index of the original tumour. Thus, we successfully established organoid 124 
cultures from 100% of the samples derived from tumours that contained > 5% proliferating 125 
cells, while we did not succeed in deriving material from very well differentiated lesions, with 126 
<5% proliferative cells in the original samples, in agreement with the histological grading of 127 
early HCCs [5] (Suppl. Fig. 2b-g and Suppl. Table 1). Of note, after the first derivation, all 128 
cultures, irrespective of their subtype-of-origin, were maintained in the same culture 129 
conditions as our already defined human healthy liver-derived organoid complete medium 130 
[23, 24] (see methods for details). 131 
PLC-derived organoids (also termed “tumouroids” from hereon) from all 3 different subtypes 132 
expanded long-term (~1year) in culture (Fig. 1d and Suppl. Fig. 2h), with a consistent 133 
passaging ratio of 1:3-1:4 every 7-10 days (Fig. 1d). HCC-2, though, stopped growing after 134 
1.5 months (passage 3), due to the presence of fibroblasts in the culture, which outcompeted 135 
the tumouroids growth and precluded any downstream analysis (Fig. 1d). Therefore, we have 136 
performed all the downstream analysis on the remaining 7 lines and corresponding patient’s 137 
tissues (HCC-1 and -3; CHC-1 and -2 and CC-1, -2 and -3).  138 
At the histological level, tumouroids presented patient-specific heterogeneous morphologies 139 
ranging from very solid, compact structures (HCC and CHC) to more irregularly-shaped cyst-140 
like structures (CC) in contrast to the ordered, homogeneous, cyst-like hollow structure of 141 
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healthy liver-derived organoids (Fig. 1b and Suppl. Fig. 2a). These morphological features 142 
allowed individual samples to be distinguished from each other, both within and between 143 
tumour subtypes, even at late passage and after having been cultured in the same medium 144 
conditions (Suppl. Fig. 2h). Also, successfully expanded tumouroids could be readily frozen 145 
and thawed, without affecting their morphological structure or expansion potential, using our 146 
previously described protocol [24]. 147 
 148 
We then sought to determine whether the 3D-tumouroids would retain the histological 149 
features of the original patient tumour tissue. Healthy liver-derived organoids form single-150 
layered epithelial structures (Fig. 1b) that transition into a pseudo-stratified epithelium upon 151 
differentiation (see [23] for details). In contrast, the tumouroids exhibited a very different 152 
histological and cellular architecture, which recapitulated the histological features of the 153 
patient’s tissue and tumour subtype (Fig. 1b and Suppl. Fig. 2a). Thus, HCC and CHC 154 
tumouroids exhibited a solid, filled 3D structure with HCCs but not CHCs also forming 155 
pseudoglandular rosettes, a typical pattern of HCC [1, 7]. Similarly, CC tumouroids exhibited 156 
extensive glandular domains with carcinoma cells forming lumen and growing in cribriform 157 
structures, as observed in the original sample (Fig. 1b Suppl. Fig. 2a).  158 
Detailed histological and marker analysis of all the patient’s tumour tissues revealed that our 159 
cultures derived from a moderate-to-well differentiated HCC (HCC-1, AFP+, HePar1+), a 160 
poorly differentiated HCC (HCC-3; AFP+, HepPar1-, EpCAM-), a classical combined (CHC-161 
1; HepPar1+, EpCAM+, mucins +), a combined with stem cell features (CHC-2; AFP+, 162 
HepPar1+, EpCAM+) and moderate-to-poorly differentiated CCs (CC-1, -2 and -3; HepPar1-, 163 
EpCAM+) (Fig. 2a-b, Suppl. Fig 3a-b and d and Suppl. Table 1) [25]. Subsequent analysis of 164 
these subtype-specific markers in the corresponding tumouroids revealed that tumour-derived 165 
organoids express the diagnostic markers of their parental tissues, even after long-term 166 
expansion in culture in the same culture conditions for the different lines. Thus, EpCAM, 167 
marker for CC and CHC tumours [3, 26] was highly expressed in all CCs (CC-1, -2 and -3) 168 
and CHCs (CHC-1 and -2) tumouroids and corresponding patients’ tissues but absent on 169 
HCCs tumouroids and corresponding patients’ tissues (Fig. 2c and Suppl. Fig.3b). Likewise, 170 
Alpha-fetoprotein (AFP), a well-established marker for HCCs and a subset of CHCs [26], but 171 
not expressed in CCs [1, 5, 27, 28], was highly expressed in both HCCs and CHC-2 172 
tumouroids but absent in all CC tumouroids and in the CHC-1 line, in agreement with the 173 
expression pattern and diagnostic of the original patient’s tissue (Fig. 2c and Suppl Table 1). 174 
Remarkably, SALL4 described for a subset of aggressive HCCs [29, 30] and a subset of CHCs 175 
[31] was present only in HCC-3 and CHC-2, both in tumouroids as well as in the 176 
corresponding patient’s tissue, but absent in all other tissues and tumouroid lines (Suppl. Fig. 177 
3c). 178 
 179 
Overall, these results demonstrate that the 3 different subtypes of liver tumour organoids both 180 
recapitulated and retained the histological characteristics and marker expression of the 181 
original tumour tissue and subtype, even after long-term expansion in culture, in the same 182 
culture conditions. 183 
 184 
Genome-wide analysis demonstrates that Primary Liver Cancer-derived organoid 185 
cultures recapitulate the expression profile of the corresponding tissue-of-origin and 186 
tumour subtype.  187 
The gene expression patterns of PLC subtypes (HCC, CC and CHC) have been extensively 188 
studied [32] and have proved useful in classifying them [33]. Therefore, to further evaluate 189 
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whether tumouroids maintain the expression profile of the original tumour, we opted to 190 
characterize in depth these novel PLC-derived organoid lines by comprehensively studying 191 
their expression profiles compared to the corresponding parental tissues using genome-wide 192 
transcriptomic (RNAseq) analysis. Healthy liver-derived organoid lines growing in expansion 193 
and differentiation medium and corresponding healthy liver tissues were used as additional 194 
controls.  195 
 196 
Strand-specific RNAseq libraries were generated from all organoid lines and corresponding 197 
tissue-of-origin (CC-1 to 3; HCC-1 and -3; CHC-1 and -2; Healthy-1 to 3). Relative transcript 198 
abundance (transcripts per million, RPKM) of 15,648 gene transcripts was determined. For 199 
some samples, several biological as well as technical replicates were run (see Dataset_1_S1 200 
for details). PCA analysis indicated that both, technical and biological replicates per patient 201 
were almost identical (data not shown). Hence, to process the data for further analyses we 202 
averaged all these technical and biological replicates of each patient tissue or organoid 203 
together and present the analysis per patient sample. Gene expression correlation analysis 204 
indicated that each tumouroid line correlated to its corresponding tissue-of-origin. Thus, 205 
HCC-1 and HCC-3 correlated with HCC-1 and HCC-3 tissues respectively, while all 3 CC 206 
tumouroid lines correlated with the corresponding CC but not HCC nor CHC tissues. 207 
Similarly, CHC tumouroid significantly correlated to their respective CHC tissues but not to 208 
the other subtypes (Fig. 3a). PCA analysis of tissues and corresponding tumouroids revealed 209 
that the samples grouped by subtype on the PC2 component, indicating that each PLC-derived 210 
organoid subtype is similar to its corresponding tissue subtype, while the PC1 component 211 
accounted for the variance between tissues and tumour-derived organoids. Classical HCC 212 
markers such as AFP or APOH and CC markers such as KRT7 or MMP7, were amongst the 213 
genes that contribute the most to the variance in the PC2 component (Fig. 3b and Suppl. 214 
Dataset 1_S2).  215 
 216 
In agreement with the expression of the original tissues, we found the genes AFP, ALB, 217 
APOH, FGG, RBP4, TF, AHSG, FGB,  (all involved in HCC progression [34]) and recently 218 
described as markers of HCC tumour-circulating cells [35], to be highly upregulated (2Log-219 
FC>6) in HCC tumouroids (Fig. 3c and Suppl. Dataset 1_S2). Also, several markers of 220 
differentiated hepatocytes (TTR, CYP2E1, APOA1, APOE) were within the most upregulated 221 
genes (2LogFC>5) while TFF2, a CC marker [36], and the ductal markers KRT7, KRT19, 222 
EPCAM and CD24 were amongst the most downregulated genes in both HCC tumouroid 223 
lines (Fig. 3b-c, Suppl. Fig. 2b, and Suppl. Dataset1 _S2-3). Similarly, in CC tumouroids, 224 
S100P, S100A11, S100A6 [37], ALDOA [38], CLIC3 and ANKRD22 [39] all commonly 225 
upregulated in CC tissues [40-42] were highly expressed, while hepatocyte (ALB, TTR, 226 
APOA1 and APOE) and HCC markers (AFP, GPC3) [34] were not expressed or strongly 227 
downregulated (Fig. 3b-c and Suppl. Dataset 1_S5), in agreement with the expression of the 228 
original CC- tumours. KRT7 and KRT19 were highly expressed in both CC-derived and 229 
healthy liver-derived organoids, as expected due to their ductal/progenitor origin (Fig. 3c, and 230 
Suppl. Dataset 1_S5). The CHC lines (CHC-1 and CHC-2) shared the expression of markers 231 
of both HCC (APOA1, TTR, GPC3) and CC (EpCAM, KRT19) tumours, as expected (Fig. 2c, 232 
Fig. 3c, and Suppl. Dataset 1_S4). Remarkably, these markers were also retained in a patient 233 
specific manner even within each subtype. For instance, MUC5B was expressed only in CHC-234 
1 but not in CHC-2 organoids, in agreement with the corresponding patient’s tissues PAS 235 
staining (Fig. 3c and Suppl. Fig. 3d), whereas AFP was expressed in CHC-2 but not CHC-1 in 236 
concordance with the AFP values in serum of these patients at the moment of resection 237 
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(compare Fig. 2c and Suppl. Table 1). 238 
 239 
Gene-Set-Enrichment-Analysis (GSEA) of the tumouroid lines and their corresponding 240 
parental tissues using 159 published cancer gene-sets (Suppl. Dataset 2_S1 and 3_S1) 241 
confirmed that the tumouroid cultures retain the gene expression profile of the specific 242 
tumour subtype they derive from, in a patient-specific manner (Fig. 3d and Suppl. Datasets 2-243 
3). Thus, for both HCC lines and corresponding tissues, HCC gene-sets were the most 244 
significantly positively enriched, with HCC-1 associated to a gene-set describing HCC with 245 
hepatocyte differentiation features while HCC-3 significantly associated with a proliferative 246 
HCC subclass and a KRT19 positive subclass gene-sets but showing a negative correlation 247 
with the gene-sets related to hepatocyte differentiation and good prognosis, in agreement with 248 
the differentiation status of the patient’s original tissue (Fig.3d, Suppl. Fig.4 a and c, and 249 
Suppl. Dataset 2 and 3). Conversely, for all CC tumouroids and corresponding tissues, CC 250 
gene-sets were the most significantly positively enriched whereas HCC specific gene-sets 251 
were significantly down-regulated as expected. (Fig.3d, Suppl. Fig.4a and Suppl. Dataset 2 252 
and 3). Similarly, the CHC expression profiles were negatively correlated with HCC-253 
differentiation gene-sets but positively correlated with progenitor/stem cell, proliferation 254 
and/or poor prognosis gene-sets (Fig.3d, Suppl. Fig.4 a and Suppl. Dataset 2 and 3).  255 
 256 
Subsequent immunofluorescent and qPCR analyses of tumouroids and associated tissues 257 
confirmed the RNAseq results indicating that the cultures retained the differentiation status of 258 
the parent tumour subtype in vitro. Thus, HCC tumouroids exhibited a high degree of 259 
hepatocyte differentiation, with high levels of HNF4a and Albumin expression and secretion 260 
(Suppl. Fig. 4d-e), with HCC-1 being the most differentiated and exhibiting high production 261 
of bile acid in the medium (Suppl. Fig. 4f). Similarly, CHC tumouroids also presented some 262 
degree of differentiation, albeit reduced compared to the HCCs, in agreement with their 263 
combined phenotype (Suppl. Fig. 4d-e). All of these hepatocyte markers were absent in CC 264 
tumouroids (Suppl. Fig 4d). In contrast, KRT19, marker for CC and CHC tumours [3, 26] and 265 
a subset of HCCs [25] was highly expressed in all CC (CC-1, CC-2, CC-3), in both CHC 266 
(CHC-1 and CHC-2) and in HCC-3 derived tumouroids, but undetectable in the most 267 
differentiated HCC-1 line, in agreement with the histological subtype, expression pattern and 268 
gene signature of the patient’s tumour tissue (Suppl. Fig. 4c-d). Similarly, KRT7, a well-269 
established marker for CCs [43], was only expressed in the CC-derived organoids and 270 
corresponding parental tissues, but not in the HCC or CHC tumouroids (Suppl. Fig. 4g). 271 
 272 
These results demonstrate that the PLC-derived organoid culture system faithfully 273 
recapitulates and maintains the transcriptomic alterations present in the individual patient’s 274 
tumour subtype. Since the different tumour subtypes were all maintained in the same culture 275 
conditions these results suggest that their tumour signature is intrinsic to the cancer 276 
population, and is not significantly modified by the culture conditions. 277 
 278 
Tumouroid/Organoid cultures allow identification of novel genes involved in liver 279 
cancer progression and potentially novel liver cancer biomarkers 280 
We next sought to investigate if the tumouroid culture system, which is enriched on the 281 
tumour propagating cells, could represent a valuable resource to identify novel genes 282 
involved in PLC progression or novel potential PLC biomarkers, a use not previously 283 
described for tumour-derived organoid systems. For that we first defined a tumouroid 284 
expression signature by comparing the similarities between the transcriptomes of all 285 
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tumouroid lines to healthy liver-derived organoid lines. We defined this gene list as 286 
“tumouroid signature” list (Fig. 3e). Notably, within the top 30 most upregulated genes 287 
(Suppl. Dataset 1_S6) we found 19 genes already reported to be markers/overexpressed in 288 
PLC, 13 of which were already associated to poor-prognosis including DANCR [44], MCM7 289 
[45], UBE2C [46] and CCNB1 [47] (Fig. 3f), thus validating our approach. From the 290 
remaining 11 genes, we found 5 genes already associated to other cancers while the 291 
remainder had never been associated to cancer. 292 
 293 
To determine the value of this tumouroid gene list for diagnostic or prognostic prediction, we 294 
performed an in-depth analysis of this top 30 genes by determining their expression pattern 295 
and prognostic value in cohorts of primary liver cancer patients and healthy individuals from 296 
publically available TCGA databases (for HCC: 374 HCC patients and 50 healthy 297 
individuals; for CC: 31 CC patients and 8 healthy individuals). Notably, 29 of the top 30 298 
genes were significantly (p≤0,01) overexpressed in cancer patients vs healthy individuals for 299 
both cohorts, HCCs and CCs (Fig. 3f and Suppl. Dataset 1_S7), thus exemplifying the value 300 
of PLC-derived organoids to identify genes involved in primary liver cancer. Of note, 18 of 301 
these genes also exhibited significant predictive prognostic value, i.e., predicted poor 302 
prognosis when overexpressed. Importantly, from these genes we found 5 novel genes 303 
associated to poor survival in the different PLC cancer cohorts: C19ORF48, UBE2S and 304 
DTYMK (for HCC) and C1QBP and STMN1 (for CC). Of note, none of these genes had been 305 
previously associated to liver cancer, except for STMN1, that had been associated to poor 306 
prognosis in HCC but not in CC [48] (Fig 3f-h). Therefore, these results demonstrate that 307 
growing primary liver cancer as tumouroids preserves the tumour-cell features at a level that 308 
allows identifying potential new genes involved in PLC progression. In addition, these genes 309 
could potentially be used as prognostic markers in primary liver cancer.  310 
 311 
Overall these results highlight two important advantages of the tumour-derived organoid 312 
culture system: (1) the ability to faithfully recapitulate and maintain the transcriptomic 313 
alterations present in the individual patient’s tumour subtype and (2) its potential for liver 314 
cancer biomarker discovery. 315 
 316 
Liver tumouroids retain the genetic alterations present in the original tumour tissue. 317 
PLCs, in particular CC, HCC and CHC, typically present with a high degree of aneuploidy 318 
and share several copy number changes, somatic mutations and epigenetic alterations [6]. All 319 
the tumouroid lines that we expanded in culture (HCC, n=2; CHC, n=2; CC, n=3) exhibited 320 
multiple chromosomal aberrations consisting of both gains and/or losses of chromosome 321 
numbers (Fig. 4a-b). This was in stark contrast to healthy liver-derived organoids that stably 322 
maintained diploid chromosome numbers in culture, in agreement with our previous 323 
observations [23] [49]. To determine whether the different tumouroid lines retain the parent 324 
tumour’s mutational landscape, we performed whole exome sequencing (WES) analysis of 325 
each liver tumouroid line expanded for short (<2 months, early passage) or extended (>4 326 
months, late passage) periods in culture and compared the results to the corresponding parent 327 
tumour.  328 
 329 
 330 
We generated ~19 Gb exome DNA sequence data from each sample. After removal of low 331 
quality reads (<Q20) and adaptor sequences, we identified and selected the variants with the 332 
following parameters: base quality ≥15 (Phred score), read depth ≥15 and annotated as not 333 
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“intergenic” (see methods for details). When comparing the mutational burden in the patient’s 334 
tissue to its corresponding tumouroid lines, we observed a strong correlation between the 335 
somatic variations of each tumouroid and corresponding original tissue (Fig. 4c). We found 336 
that an average of ~92% of the somatic variants in the patient’s tissue were retained in the 337 
corresponding early tumouroid cultures (<2months), and >80% even after months of 338 
expansion (Fig. 4c). Similarly, the analysis of the number of mutations for both patient’s 339 
tissue and corresponding tumouroid cultures confirmed that the global SNV number as well 340 
as the number of indels in the original patient tissue is well retained in culture, even at late 341 
passage (Fig. 4f). The distribution of somatic base substitutions for both tissues and organoids 342 
revealed an over-representation of the nucleotide transversion T>C/A>G and C>T/G>A, in 343 
agreement with the mutational spectrum described for CCs and HCCs [50, 51] (Fig 4d-e). Of 344 
note, we did not find significant bias between transcribed and untranscribed strands (Suppl 345 
Fig. 5a). After applying an additional filtering step aimed at identifying cancer related 346 
variants (filtering SNVs present in COSMIC databases but excluding dbSNPs) we also found 347 
that the majority of all the cancer-related somatic variants present in the patient’s original 348 
tissue (>75%) were retained in the corresponding tumouroid cultures in both early and late 349 
passage. In fact, <10% of these cancer-related variants were lost between tissue and early 350 
organoids, thus suggesting that the cultures represent the tumour genetic landscape of the 351 
original patient with little bias for sub-populations of tumoral cells harbouring specific 352 
mutations (Fig. 4f). 353 
 354 
The detailed analysis of the specific somatic mutations present in both tissues and 355 
corresponding organoids, showed that all lines harboured the TP53 missense variant P72R, 356 
with CHC-2 also presenting 1 additional frameshift variants (L206fs) (Fig. 4g and Suppl. 357 
Dataset 4). In addition, HCC-1 and HCC-3 lines exhibited missense mutations in CTNNB1, 358 
while the Wnt negative regulator RNF43 was found mutated only in CC-derived tumouroids 359 
(Fig. 4g and Suppl. Dataset 4) in agreement with the differential mutational pattern of these 2 360 
components of the Wnt pathway in these 2 subtypes of liver tumours [52, 53, 54]. 361 
Consequently, these results correlated with the significant enrichment in β-catenin mutated 362 
liver cancer datasets for HCC-1 (Fig. 3d) and the ability of HCC but not CC lines to grow and 363 
express the Wnt target genes TNFSRF19, AXIN2 and LGR5 in the presence of the porcupine 364 
inhibitor IWP2 in the medium (Suppl. Fig. 5d-e). Similarly, we also identified mutations in 365 
KRAS (KRASG12D) in CC-1 and CHC-1 tumouroids but not in the other lines, in agreement 366 
with the transcriptomic analysis, which showed significant enrichment in published EGF 367 
activated dataset (Suppl. Fig. 5c) [55]. Notably, we found nonsense mutations (frameshifts or 368 
stop-gains) in the chromatin remodelling genes ARID1A (HCC-3 and CC-1), ARID2 (HCC-3) 369 
and BAP1 (CHC-1), in agreement with previous reports that have highlighted the importance 370 
of these genes in both types of primary liver cancers [56, 57] (Fig.4g, and Suppl. Dataset 4). 371 
All lines were devoid of mutations in MAPK1 and MAPK3 (ERK1 and ERK2 respectively) 372 
(Fig. 4g), in agreement with previous studies in primary liver cancer [58]. 373 
 374 
Therefore, these results indicate that the PLC tumouroid culture system retained the 375 
mutational landscape of the original tumour tissue and faithfully retained the tumour-specific 376 
mutations present in the original sample from which where derived. 377 
 378 
 379 
Tumouroids recapitulate parent tumour histology and metastatic potential in vivo 380 
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To determine whether tumouroids also recapitulate the features of a human primary liver 381 
tumour in vivo, we transplanted CC (CC-1, -2 and -3 lines) and HCC-1 long-term expanded 382 
tumouroids under the skin of immunocompromised mice (Fig. 5 and Suppl. Fig. 6). Healthy 383 
liver-derived organoids were used as controls. We found tumour outgrowths in the animals 384 
engrafted with CC-1_O (29/29), CC-2_O (8/8) and HCC-1_O (24/34) (Fig. 5b and Suppl. 385 
Fig. 6a-b). As expected, healthy liver-derived organoids (Healthy-1_O) did not generate any 386 
tumoural mass in any of the animals engrafted (Fig. 5b and Suppl. Fig. 6b). The CC- derived 387 
tumours exhibited a strong stromal reaction and a histological pattern that closely resembled 388 
the architecture of the patient’s tumour tissue. Thus, CC-1_O tumours presented with 389 
proliferative KRT19+ cells forming glands with cribriform structures (Fig. 5d), while CC-390 
2_O tumours exhibited a more differentiated phenotype, reminiscent of the CC-2-patient 391 
original tissue (Suppl. Fig.6d). Similarly, HCC-1_O derived tumours grew as a solid mass 392 
that recapitulated the histological architecture of the original HCC tumour with 393 
pseudoglandular rosettes present also in the grafted tissue (Fig.5e). Of note, secondary 394 
tumouroids could be derived from the xenografted tumours. These exhibited similar 395 
chromosome counts and were morphologically and histologically indistinguishable from their 396 
parental tumouroid line (Suppl. Fig.6g-h), thus indicating that even after long-term expansion 397 
in vitro and transplantation in vivo, expanding primary liver tumours of both HCC or CC 398 
subtypes in organoid culture methods, stably preserves the histological architecture of the 399 
parent tumour.  400 
Liver cancer has been reported to metastasize primarily to the lung and portal lymph nodes 401 
[59]. To determine whether our tumouroid models would faithfully recapitulate liver cancer 402 
metastatic phenotype, we injected a line derived from a patient with history of metastasis 403 
(CC-1_O) into the kidney capsule of NSG mice (Fig.5c). As expected, 100% of the injected 404 
mice developed tumours that resembled the original patient tissue (Fig.5f). More importantly, 405 
in 7 out of 9 of the injected mice we also found secondary metastases in the lung (Fig.5c and 406 
g and Suppl. Fig.6f), in agreement with the patient’s diagnostic at the moment of resection, 407 
where metastatic nodules had been detected (Suppl. Table 1). Healthy liver-derived organoids 408 
(Healthy-1_O) did not generate any metastases, as expected (Fig. 5c and g and Suppl. Fig.6f). 409 
 410 
Overall, these results establish that primary liver cancer-derived organoids accurately model 411 
the histological and metastatic features of their parent tumours in vivo, even after long-term 412 
expansion in culture.  413 
 414 
Liver tumouroids allow the identification of patient-specific drug sensitivities and 415 
highlight ERK as a potential target for liver cancer  416 
 417 
We performed proof-of-concept drug sensitivity testing in 6 of the PLC tumouroids lines 418 
(HCC-1, HCC-3, CHC-1, CHC-2, CC-1 and CC-2) to evaluate their use to identify patient-419 
specific sensitivities and as a platform to inform drug development. As an initial prioritization 420 
step, for each tumouroid line we tested their sensitivity to 29 anti-cancer compounds targeting 421 
key proteins and pathways implicated in cancer, including several drugs in clinical use or 422 
development. Tumouroids were plated on BME-coated 384-well plates and treated with a 7-423 
point, half-log dilution series of each compound for 6 days, before measuring cell viability 424 
[60]. Drug sensitivity was represented by the area under the dose response curve (AUC) (Fig. 425 
6a and c, Suppl. Dataset 5) and by the half-maximal inhibitory concentration (IC50) (Fig. 6c 426 
and Suppl. Dataset 5). The assay was conducted with technical replicates and two biological 427 
replicates per tumouroid were independently screened. 428 
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There was a positive correlation of biological AUC replicates (Rp = 0.79) and IC50 replicates 429 
(Rp = 0.73) across the dataset. Observed variation was in part due to the large size of 430 
tumouroids leading to uneven distribution in screening wells. CC-2 was insensitive to all 431 
compounds in the screen and so was excluded from further analyses. Overall, tumouroids 432 
were resistant to the majority of the compounds, with an IC50 greater than the maximum 433 
screening concentration, although we detected interesting sensitivity to several compounds 434 
(Fig.6a-c). For instance, we found all lines were resistant to the MDM2 inhibitor nutlin-3a, in 435 
agreement with all of them harbouring TP53 mutations. Similarly, HCC-1 and HCC-3, 436 
harbouring mutations in b-catenin, were resistant to the porcupine inhibitor LGK974, whereas 437 
CC-1 was sensitive (Fig 6a-c), in concordance with our previous results with another 438 
porcupine inhibitor, IWP2 (Suppl. Fig 5d-e). We observed tumouroid sensitivity to 439 
Gemcitabine, which is used clinically for the treatment of PLC patients (Fig 6a-c). 440 
 441 
From our initial prioritization screen, we confirmed drug sensitivity for a subset of 442 
compounds using a tumouroid formation assay. We selected clinically relevant compounds 443 
where differential sensitivity was observed across the tumouroid panel; namely Taselisib, 444 
Gemcitabine, AZD8931, SCH772984 and Dasatanib (Fig. 6c-d). Overall, a good agreement 445 
between the screening and validation results was observed (suppl.Figure 7a). An exception 446 
was for CC-1 line with AZD8931, where we observed a variable sensitivity between 447 
biological replicates in the prioritization screen. The validation screen confirmed that PI3Kα 448 
inhibition with the preclinical compound Taselisib (10μM) resulted in a growth inhibitory 449 
effect in 5 of 6 tumouroids, in line with all these tumouroids being WT for PIK3CA and 450 
RSK2 (RPS6KA3). EGFR-family inhibition with 5μM AZD8931 restricted tumouroid 451 
formation in HCC-1 cells, whereas the other lines were resistant. Sensitivity to EGFR 452 
inhibition in HCC-1 cells was confirmed with a second EGFR inhibitor Gefitinib, which was 453 
not present in our screen (Suppl.Fig.7b). Similarly, Dasatinib (2μM) suppressed tumouroid 454 
formation in CC-1 cells, in agreement with our screening results (Fig.6 c-d). 455 
 456 
Of particular interest was the substantial inhibition of tumouroid formation following 457 
inhibition of ERK1/2 by SCH772984 in both HCC lines, as well as in the other tumouroid 458 
subtypes, CC-1 and CHC-1 cells (Fig. 6a-d and Suppl. Fig.7a). SCH772984, which 459 
selectively inhibited ERK-phosphorylation in HCC-1 and CC-1 tumouroids (Suppl. Fig.7f), 460 
was effective in lines that were insensitive to the BRAF and/or MEK inhibitors in our screen 461 
(Dabrafenib and Trametinib) (Fig.6c). The reason for this difference is unclear, although ERK 462 
inhibitors have demonstrated activity in cells with acquired BRAF and MEK inhibitor-463 
resistance [61].  464 
We note that clinical trials exploring the effect of specific ERK inhibitors for PLC have not 465 
been reported thus far. Hence, to further investigate the potential of ERK1/2 inhibition for 466 
PLC, we tested the efficacy of SCH772984 to inhibit tumour growth in vivo. For that, CC-1 467 
and HCC-1-derived tumouroids were transplanted subcutaneously into NSG mice and, when 468 
tumours reached a mean volume of ~100mm3, we injected them intra-tumourally with either 469 
SCH772984 or with the vehicle for a 10 to 15 day period. Remarkably, 2-7 days after the first 470 
injection we observed a significant reduction in tumour growth, which lasted for the 471 
remainder of the experiment up to 24 days (Fig.6e and Suppl. Fig. 7d). Histological analysis 472 
of the tumours from both CC-1 and HCC-1 lines at 24-25 days after treatment initiation, when 473 
a significant tumour regression was observed, revealed that the tumour mass was necrotic and 474 
that the majority of the cells were apoptotic (Fig.6f-g and Suppl. Fig. 7e). Western blot 475 
analysis from tumours treated for 6 hours with either SCH772984, or with the vehicle control, 476 
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confirmed that SCH772984 also in vivo selectively inhibited ERK-phosphorylation in CC-1 477 
tumours (Suppl. Fig. 7g). Thus, in aggregate, our proof-of-concept study demonstrates the 478 
application of PLC tumouroids for in vitro and in vivo drug testing, and provides initial 479 
evidence that ERK inhibition could have a beneficial therapeutic effect on a subset of HCC 480 
and CC patients.  481 
 482 
Overall, these results indicate that by faithfully retaining the histological, transcriptomic and 483 
genomic landscape of their parent tumour, tumouroid cultures facilitate the prediction of drug 484 
sensitivity/resistance in a patient-specific manner. They therefore, provide an important new 485 
resource for liver cancer research, opening up new avenues for biomarker discovery and drug 486 
testing as well as to gain further insights of the origin and progression of an increasingly 487 
prevalent disease. 488 
  489 
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DISCUSSION 490 
 491 
The advent of 3D culture systems has made it possible to partially recapitulate the complexity 492 
and function of mammalian tissue in vitro, by forming structures that resemble an adult organ 493 
in culture and which have been termed “organoids” [15]. Based on the knowledge from small 494 
intestine, we recently have demonstrated that gastric, pancreatic and hepatic organoid cultures 495 
derived from either adult mouse or human tissues self-renew and differentiate in vitro, into 496 
the corresponding cell types of the tissue-of–origin [14, 15]. 497 
 498 
Here, we demonstrate the proof-of-concept that primary liver cancer (PLC) tissue grown as 499 
organoid cultures (here termed tumouroid) faithfully models the genetic complexity of human 500 
PLC in vitro. We successfully established cultures from tumours derived from 8 PLC patients 501 
representing the three most common subtypes of PLC [1]: HCC, CC and CHC. In contrast to 502 
any liver cancer cell line grown in 2D, PLC-derived organoids recapitulate the histological 503 
architecture and expression profiles of the corresponding parent tumour, even after being 504 
cultured long-term in the same culture conditions for all subtypes or upon transplantation into 505 
mice. Notably, they also retain the specific differences between patients as well as between 506 
tumour subtypes. We have exploited this aspect here to demonstrate that tumour-derived 507 
organoid cultures represent a valuable resource for biomarker discovery, especially for 508 
prognostic markers, an application not previously reported for any organoid culture system. In 509 
fact, tumour organoids encompass cells with long-term self-renewal capacity but are devoid 510 
of any stromal component. This represents an advantage for gene discovery, as it facilitates 511 
enrichment of the tumour propagating population, thus facilitating the identification of 512 
relevant genes involved in liver cancer and potential new biomarkers. Here we report 513 
C19ORF48, UBE2S, DTYMK, C1QBP and STMN1 as all novel predictors of poor prognosis 514 
for primary liver cancer. These results open up novel opportunities in using tumour-derived 515 
organoids for tumour marker discovery. 516 
 517 
A unique and important feature of the tumouroids is that they maintain the mutational 518 
landscape of the original patient’s tumour, even after long-term expansion in culture or 519 
following transplantation and derivation into secondary organoids. This is vastly different to 520 
existing 2D cell lines, which albeit they cover the major driver mutations observed in many 521 
cancer sub-types [62], no longer present the patient-specific signature and genetic landscape 522 
of the original tumours from whence they were derived, exemplified by the frequent 523 
acquisition of mutations in p53 in such cell lines [63]. The reasons for these differences are 524 
unknown, but it is feasible to speculate that the cell-matrix interactions may play an important 525 
role. In fact, embedding primary tumoural epithelial cells within an extracellular matrix 526 
(ECM) enables the cells to interpret the environment and self-assemble into structures which 527 
acquire tissue patterning, as it occurs during development and organogenesis. Also, the cell-528 
matrix interactions established in 3D could prevent anoikis-apoptosis due to detachment from 529 
the matrix[64] of those tumoural cells that have not acquired yet all the mutations to survive 530 
in a ECM-free milieu, thus facilitating the maintenance of heterogeneous, non-selected 531 
populations within the culture. In that line, our results indicate that if selection of specific 532 
tumoural cells exist in the cultures, this might have a minor effect at the population level, as 533 
we found that tumouroids harbour >92% of the mutations present in the original tissue.  534 
 535 
The reproduction of parent tumour genetic aberrations in a culture setting makes tumouroid 536 
lines a potentially valuable resource in screening drug sensitivity/resistance, identifying novel 537 
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players in liver cancer progression, or even novel therapeutics as part of a personalized 538 
medicine approach. Our results validate such an approach by (1) demonstrating a correlation 539 
between drug sensitivity and mutational profile in the tumouroid lines and (2) the de novo 540 
identification of the ERK inhibitor SCH772984 as a potential novel therapeutic agent for liver 541 
cancer.  542 
The lack of immune system and stromal components, though, represents a limitation of the 543 
culture system, especially when aiming at studying tumour cell-stroma/immune interactions. 544 
In that regard, patient derived xenografts (PDXs) have proven useful models for human 545 
cancer, including liver cancer [13, 65], as they also retain tumour histopathology, including 546 
tumour-infiltrating lymphocytes and the stromal component, and global gene expression and 547 
methylation profiles of the patient’s malignant epithelial cells [66]. However, PDXs suffer 548 
from a low engraftment rate, especially CCs (5.8% engraftment efficiency as reported by 549 
[13]), have a long engraftment period (often several months), they are expensive and time-550 
consuming, and are not tractable for large-scale drug sensitivity testing [66]. Therefore, we 551 
believe that the PLC-derived organoid cultures we present here are complementary and 552 
alternative models to liver cancer PDXs. Specifically, the derivation efficiency is ~75%, 553 
especially for CC, and is significantly shorter than for PDX. Furthermore, they are suitable 554 
for large-scale drug testing, and in a timescale that makes potentially compatible with 555 
personalized medicine approaches. 556 
 557 
In conclusion, the PLC-derived organoids that we present here fulfil all the criteria of a 558 
reliable in vitro cancer model, recapitulating all the features of three of the most common 559 
subtypes of liver tumours, from histological architecture to genetic and transcriptomic traits, 560 
and are amenable as a platform for drug testing. With a short timescale from establishment to 561 
drug testing, this novel in vitro liver cancer system thus makes hitherto inaccessible 562 
possibilities for predicting patient-specific drug responses and creating personalized/à la carte 563 
therapies into a reality. 564 
 565 
  566 
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FIGURE LEGENDS 779 
Figure 1: Patient-derived primary liver cancer organoid cultures expand long-term in 780 
vitro while preserving the histological architecture of the specific subtype of primary 781 
liver tumour they derived from.  782 
(a) Experimental design. For each tissue, samples were split into 4 parts and processed for 783 
histology, RNA and DNA isolation, or dissociated and processed for organoid culture. 784 
Healthy (donor-derived) liver tissues, moderate/well differentiated hepatocellular carcinoma 785 
(HCC), combined hepatocellular-cholangiocarcinoma (CHC) and cholangiocarcinoma 786 
samples (CC) were obtained from patients undergoing surgery (patient’s information detailed 787 
in Supplementary Table 1) and were processed as described in Methods and Suppl. Fig.1. (b) 788 
Representative H&E staining of healthy liver tissue and primary tumour (top row), and 789 
corresponding brightfield microscopy images (middle row) and H&E histological analysis of 790 
the organoid lines derived from these (bottom row). Note that, while healthy liver-derived 791 
organoids (left) grew as single layered epithelium of ductal-like cells surrounding a central 792 
lumen (*, duct; L, lumen), tumour-derived organoids (= tumouroids) formed solid/compacted 793 
structures that resembled the corresponding tumour-of-origin [compare tissue (top row) with 794 
the corresponding organoid histology (bottom row)]. HCC-1 tumouroids exhibit 795 
pseudoglandular rosettes (arrowheads, bottom row), a hallmark of HCC, also found in the 796 
parent tumour tissue (arrowheads, top row). CC-1 tumouroids, present a glandular lumen, 797 
similar to the original patient’s tumour (top row). Scale bars, middle rows 100µm; top and 798 
bottom rows, 50µm. Brightfield and H&E pictures from other lines are provided in Suppl. 799 
Fig. 2. (c) Organoid formation efficiency in classical human healthy liver isolation medium 800 
(see Broutier et al, 2016 for details) and tumouroid specific isolation medium (classical 801 
human healthy liver complete medium without RSPO + 3nM Dexamethasone - see Methods 802 
and Suppl. Fig1 for details). Graph represents mean±SD of the total number of tumouroids 803 
obtained per well of each condition. (d) Expansion potential of tumouroid cultures established 804 
and their correlation to the expansion of healthy-tissue derived organoids. Arrow, continuous 805 
expansion. Dot, passage. 806 
 807 
Figure 2: Immunohistochemistry analyses reveal that the PLC tumouroids retain 808 
expression patterns of the distinct subtype of the original tissue they derived from, even 809 
after long-term expansion in culture.  810 
(a) Schematic representation of the multiple subtypes among types of primary liver cancers 811 
(PLC). (b) IHC assays on the PLC tissues including hepatocyte/HCC marker (HepPar1) and 812 
ductal/CC marker (KRT19). Scale bar, 125 μm. Dashed red square indicates focal staining. (c) 813 
Immunofluorescent analysis for the HCC marker AFP (in red) and the ductal/CC marker 814 
EpCAM (in green), on tumouroids expanded in culture for at least 3 months. Nuclei were 815 
counterstained with Hoechst33342. Scale bar, 30µm. 816 
 817 
Figure 3: Genome wide gene expression analysis indicates that the tumouroids 818 
recapitulate the expression profile of the specific subtype of primary liver cancer (PLC) 819 
they were derived from and allow identifying potential new genes involved in PLC. 820 
(a) Correlation heat map between PLC-tissue ( _T) and paired PLC-derived organoid line ( 821 
_O) expression profiles showing that the tumourigenic profile of the original tissue and 822 
specific subtype of PLC is maintained after long-term expansion in culture. Red, strong 823 
correlation; blue, low correlation. (b) PCA analysis showing samples plotted in 2 dimensions 824 
using their projections onto the first two principal components (PC1 and PC2). Each data 825 
point represents one sample, dot stands for tumouroids lines, triangle for PLC tissues. PC1 is 826 
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strongly correlated with the type of sample (tumouroids vs tissue) whereas PC2 defines the 3 827 
different PLC subtypes (HCC, CHC and CC). Of note, tumouroid lines and tissues are 828 
distributed consistently along PC2 according to their own PLC subtype. Some genes from the 829 
top 100 genes with highest loadings across PC2 are shown. (c) Heat map analysis of the log2 830 
RPKM values (raw z-scored) of selected genes found highly expressed (red) in HCC and/or 831 
CHC and/or CC tumouroids. (d) Gene set enrichement analysis (GSEA) comparing the 832 
tumouroid lines’ and associated tissues’ gene expression signatures to 159 curated gene-sets 833 
associated with liver cancer and stem cell (representative plots shown in Suppl. Fig. 4). The 834 
heatmap shows some of the significantly UPregulated and DOWNregulated gene-sets (False 835 
discovery rate (FDR)<25%) in the tumouroid lines and paired tissues. Full list of gene-sets 836 
and significantly enriched gene-sets can be found in Suppl. dataset 2 and 3. (e) Schematic of 837 
the tumouroid signature. Venn diagram overlapping the upregulated genes in each tumouroid 838 
line compared to healthy organoids. (f) Table summarizing the results of the gene expression 839 
patterns (OE, overexpression) and outcome prediction (KM, Kaplan-Meier) analyses 840 
performed for the top genes of the tumouroid signature using publically available TCGA 841 
cohorts. The table details the p-values obtained for each analysis (OE in PLC, two-sided t-test 842 
; KM analysis, log-rank test). p-value≤0.05 are defined as significant and color coded using 843 
yellow in the table. Only top the 25 genes are represented (Top 30 genes analysis and 844 
corresponding values can be found in Suppl. dataset 1). TCGA-HCC, 374 tumoural /50 845 
normal samples; TCGA-CC, 31 tumoural /8 normal samples. (g) Box plots for the expression 846 
of STMN1, C1QBP and C19orf48 in tumoural and normal tissues using the TCGA-HCC 847 
and/or CC cohorts. (h) Kaplan-Meier analyses in the TCGA-HCC and/or TCGA-CC cohorts 848 
based on the expression level of the gene of interest (STMN1, C1QBP and C19orf48) in the 849 
tumoural samples. 850 
 851 
Figure 4: Tumouroids recapitulate the genetic alterations present in the patient’s 852 
tumour.  853 
(a) Ploidy analysis of tumouroid cultures expanded for at least 2 months in culture. Results 854 
are expressed as % of ploidy per number of metaphases counted (at least 25 total). Healthy-855 
derived organoids were used as control. Experiment was performed at least in duplicate. (b) 856 
Representative images of organoid metaphases used for the ploidy analysis. (c-g) All somatic 857 
variants identified in all samples (21 total; 7 patients with 3 samples (Tissue/early 858 
organoid/late organoid)) were used for the global analyses after filtering for quality control as 859 
detailed in methods (c-e). For f-g, an additional filtering step was applied: a cancer related set 860 
of variants was defined by adding the following filtering steps: (1) SNVs, which were 861 
included in dbSNP were excluded, with the exception of those which were also included in 862 
COSMIC database (resultant variants are detailed in Fig. 4f and Suppl. Fig. 5b). (2) 863 
Synonymous SNVs were filtered out as were assumed to be unlikely involved in cancer. (3) A 864 
last filtering step was performed selecting for variants present in a panel of genes described in 865 
literature to be involved in cancer (847 cancer related genes total, for details see Suppl. 866 
Dataset 4). Resultant variants are provided in Suppl. Dataset 4 and were used to select 867 
relevant mutations described in Figure 5g. (c) Correlation heat-map between PLC-tissues ( 868 
_T) and PLC-tumouroids ( _O) variants identified. (d) Proportions of somatic variants across 869 
the samples, the 6 types of SNVs and the indels are represented. (e) Percentage of the 6 types 870 
of SNVs averaged across all samples (21 total; 7 patients with 3 samples (Tissue/early 871 
organoid/late organoid samples)). Graph represents mean±SD. (f) Bar plots indicate the 872 
concordance between the cancer related somatic variants identified in the tumour-of-origin 873 
and the corresponding tumouroids expanded for short or long term in culture. (g) Genes 874 
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altered in tumouroid cultures and associated tissues and known to be mutated in liver OR 875 
gastrointestinal tumours. The type of mutation is indicated in the legend. OxS, oxidative 876 
stress. 877 
 878 
Figure 5: PLC tumouroids recapitulate patient’s PLC tumour subtype and metastasis in 879 
vivo when transplanted in mice. 880 
(a) Experimental design. PLC tumouroids or Healthy liver-derived organoids expanded for >3 881 
months in culture were transplanted subcutaneously (SC) or under the kidney capsule 882 
(Kid.Cap.) of immunocompromised NSG mice and analysed for the presence of tumour 883 
growth and metastasis following grafting. (b-c) Tables summarizing the number of cells, site 884 
of engraftment and analysis of tumour and lung metastasis. No tumour lesions were found in 885 
any of the mice receiving Healthy-1 organoids. Tumours were dissected at 1 (CC-1_O and 886 
Healthy-1_O) and 5 (HCC-1_O and Healthy-1_O) months  (SC graft) and 0.5, 1, 2 and 3 887 
months (Kid.Cap. graft) after injection. (d) Representative H&E staining of CC-1 tumouroids 888 
transplanted subcutaneously (top) into NSG mice and corresponding CC-1 patient’s tumour 889 
sample (bottom). Note that the grafted CC-1 tumouroids tissue (top) recapitulates the histo-890 
architecture of the patient’s original tumour (bottom) including the extensive desmoplasia 891 
found on the CC-1 original sample (arrowheads). Scale bars, top left 250µm, top right 892 
125µm, bottom left 125µm, and bottom right 62.5µm. (e) Representative H&E staining of 893 
HCC-1 tumouroids transplanted subcutaneously (top) into NSG mice and corresponding 894 
HCC-1 patient’s tumour sample (bottom). Note that the grafted HCC-1 tumouroids tissue 895 
(top) recapitulates the histo-architecture of the patient’s original tumour (bottom) including 896 
the pseudoglandullar rosettes, hallmark of HCC-1 original sample (dashed circle). Scale bars, 897 
left 125µm, right 62.5µm. (f) Representative H&E (left) and KRT19 (right) 898 
immunohistochemistry analyses of CC-1 tumouroids transplanted under the kidney capsule of 899 
NSG mice. Scale bars, 125µm. (g) Lung metastases derived from the human CC-1 900 
tumouroids transplanted under the kidney capsule cells (right panels) were identified using a 901 
human specific KRT19 antibody. No metastases were found in the lungs of mice transplanted 902 
with Healthy-1 organoids (left panels). Scale bars, 500µm, magnification 125µm. 903 
 904 
Figure 6. PLC tumouroid lines are a valuable resource for drug screening and allowed 905 
identification of ERK as a potential target for primary liver cancer. 906 
(a) Scatterplot of 1-AUC values from two biological replicates of the drug screening data, 907 
highlighting drugs inducing a viability effect in five liver tumouroid lines. Each data point is 908 
the 1-AUC value for a given drug in a particular tumouroid line. (b) Dose-response curves 909 
after 6 days treatment with Gemcitabine, Nutlin-3a, LGK974 and SCH772984 generated from 910 
the luminescent signal intensities. Data displayed are average of the technical and biological 911 
replicates. (c) Summary of the different drugs used in the drug screening, the associated 912 
pathway and nominal targets and the screen results represented as a summary of the the 1-913 
AUC and IC50 data generated for the different tumouroid lines. Red, IC50 within the screen 914 
range; Dense dotted pattern, 1-AUC>0.15 and dose response; scattered dotted pattern, 1-915 
AUC>0.15 and sensitivity at highest value only. Compounds highlighted in yellow were 916 
selected for further validation. (d) Validation of viability effects of a subset of compounds 917 
using an organoid formation assay (see details in methods). (e) In vivo activity of SCH772984 918 
in CC-1_O tumouroids grafted under the skin of NSG mice. Mice were treated with 919 
drug/vehicle twice daily for 20 days (n=5 in 2mg/kg of SCH772984 group, n=8 in vehicle 920 
group). From day 7 onwards, significant differences between the SCH772984 and the vehicle 921 
treated groups were observed. *, p-value<0.01; **, p-value<0.002 (Mann Whitney test, two-922 
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tailed). Results are shown as percentage of the tumour volume relative to day 0 (mean ±SD). 923 
(f-g) Histological analysis of the antitumor efficacy of SCH772984 on CC-1_O tumors was 924 
assessed 24 days after starting the treatment. Representative (f) H&E and (g) TUNEL staining 925 
performed on tissue sections from CC-1_O tumours treated with either vehicle (left) or 926 
SCH772984 (right). Representative images from 2 independent experiments are shown. Scale 927 
bar, 125μM (H&E) and 25μM (TUNEL). 928 
 929 
Supplementary Figure 1: Isolation and culture of human primary liver cancer-derived 930 
organoids. 931 
We successfully established and expanded human PLC-derived organoids from 7 different 932 
PLC patients, including poorly to moderate/well differentiated HCC (n=2), CC (n=3), and 933 
combined HCC/CC (CHC; n=2) by adapting the protocol to isolate and expand liver 934 
stem/progenitor cells (Huch et al, 2015) for the timing of tissue digestion (2-3 hours to 935 
overnight (O/N) according to the degree of liver fibrosis in the liver biopsy), for the starting 936 
culture conditions (tumouroid specific isolation medium (IM)) and closely monitoring the 937 
developing organoid structures (in classical IM, healthy organoids might arise, depending on 938 
the type of biopsy/resection. In those cases, these are hand-picked upon visual inspection). 939 
MWP, multi well plate; ROCKi, Rho kinase inhibitor (Y-27632). 940 
 941 
Supplementary Figure 2: Patient-derived PLC organoid cultures expand long term in 942 
vitro. 943 
(a) Tissues (top row) and tumouroids (middle and bottom rows) obtained from HCC-2, HCC-944 
3, CHC-2, CC-2 and CC-3 patients. H&E staining of the tumoural tissues (top), brightfield 945 
(middle) and H&E staining (bottom) pictures of tumouroids originated from the 946 
corresponding tissues. Scale bars, 125µm (top), 200µm (middle) and bottom 40µm, 125µm, 947 
125µm, 125µm and 70µm (left to right, respectively). (b-f) Representative Ki67 nuclear 948 
staining performed on patient’s tissues included in the study: (b) moderately differentiated 949 
HCC (HCC-1,-2), poorly differentiated HCC (HCC-3), (c) CHC (CHC-1 and CHC-2), (d) 950 
moderately differentiated CC (CC-1,-2) and poorly differentiated CC (CC-3), (e) well 951 
differentiated HCC (wHCC-8) and (f) well differentiated CC (wCC-1). Scale bars, 125µm. 952 
(g) Ki67-labelling index in PLC tissue samples. The percentage of tumour cells that are 953 
positive for nuclear Ki67 labelling was determined by counting a minimum of 1000 cells per 954 
patient in at least 2 independent slides. Graph represents mean±SD. (h) Brightfield pictures of 955 
long-term expanded tumouroid cultures. Scale bar, 200µm. 956 
 957 
Supplementary Figure 3: Immunohistochemistry and gene expression analyses reveal 958 
that the PLC tumouroids retain expression patterns of the distinct subtype of the 959 
original tumour they derived from.  960 
(a) IHC analysis for the hepatocyte/HCC marker HepPar1 and the ductal/CC marker EpCAM 961 
on CC-3 tissue ( _T). Scale bar, 125 μm. (b-c) Gene expression analysis (q-RT-PCR) of (b) 962 
ductal EPCAM and (c) progenitor SALL4 genes in both tumour tissues and respective 963 
tumouroid lines. q-RT-PCR data are normalized to the expression of the housekeeping gene 964 
HPRT. Graph represents mean±SD of at least 2 independent experiments. (d) PAS-diastase 965 
staining on tumoural tissues. Arrowheads mark positive PAS-diastase staining in CHC-1, CC-966 
1 and CC-3 tissues ( _T). Scale bar, 62.5 μm. 967 
 968 
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Supplementary Figure 4: Gene expression, immunohistochemistry and functional 969 
analyses reveal that the tumouroids retain the differentiation state of their original 970 
tissue, even after long-term expansion in culture. 971 
(a) Representative GSEA plots for 2 gene-sets associated with PLC differentiation [HCC with 972 
hepatocyte differentiation features (Hoshida et al., 2009) and cholangiocarcinoma (Andersen 973 
et al., 2012)] enriched in the tumouroid lines (_O). +, significantly upregulated; -, 974 
significantly downregulated and ns, non significant (FDR>25%). (b) IHC of the ductal/CC 975 
marker KRT19 in tissues. Scale bar, 125 μm. (c) Representative GSEA plots for 1 gene-set 976 
describing genes positively correlated with KRT19 expression (Govaere et al., 2013) 977 
significantly up or down regulated in the tumoural tissues (_T). +, significantly upregulated; -, 978 
significantly downregulated. (d) IF analysis for the ductal/CC marker KRT19  (in green) and 979 
the hepatocyte markers ALB and HFN4A (in red) on tumouroids expanded in culture for at 980 
least 3 months. Nuclei were counterstained with Hoechst33342. Scale bar, 30µm. (e) 981 
Albumin secretion was assessed by ELISA in the supernatant from HCC and CHC 982 
tumouroids. (f) Total bile acid production determined by colorimetric assay in HCC 983 
tumouroids. (g) Gene expression analysis (q-RT-PCR) of the ductal gene KRT7 in both 984 
tumour tissues and respective tumouroid lines. q-RT-PCR, data values are normalized to the 985 
expression of the housekeeping gene HPRT. All graphs represents mean±SD of 2 986 
independent experiments. 987 
 988 
Supplementary Figure 5: Tumouroids recapitulate the genetic alterations present in the 989 
original tumour.  990 
(a-b) WES analysis of patient’s tumoural tissues and corresponding tumouroid cultures 991 
expanded for < 2 months (early passage) or >4 months (late passage) in culture. All somatic 992 
variants identified in all samples (21 total; 7 patients with 3 samples (Tissue/early 993 
organoid/late organoid)) were used for the global analyses after filtering for quality control as 994 
detailed in methods (a). For (b) an additional filtering step was applied: a cancer related set of 995 
variants was defined by adding the following filtering steps: (1) SNVs that were included in 996 
dbSNP were excluded, with the exception of those also present in COSMIC database. (a) 997 
Percentage of the 6 types of SNVs on transcribed and non-transcribed strand averaged across 998 
all samples. Graph represents mean±SD. (b) Summary table describing the somatic acquired 999 
alterations present in all 3 samples per patient (tissue, tumouroids early and late passage) (see 1000 
details in methods). The median, mean, minimum (min) and maximum (max) number of 1001 
alterations across patients are indicated. (c) Representative GSEA plots for 1 gene-set 1002 
describing genes up-regulated in tumours developed by transgenic mice overexpressing an 1003 
EGF secreted form in liver (Borlak et al., 2005) significantly positively enriched in some of 1004 
the tumouroid lines ( _O). +, significantly positively enriched (FDR<25%, p-value<0.05); ns, 1005 
non significant (FDR>25%). (d) Tumouroids cultures were tested for their sensitivity to 1006 
porcupine inhibitor IWP2 (3 μM). Representative bright field microscopy images (1 out of 3 1007 
independent experiments). Scale bars, 500um and 100 um (insets). (e) Gene expression 1008 
analysis (q-RT-PCR) of the Wnt target genes TNFRSF19, AXIN2 and LGR5 on IWP2 treated 1009 
cultures. Gene expression was normalized against a housekeeping gene (HPRT) and fold 1010 
change was calculated relative to the expression on the vehicle-treated control (DMSO 1011 
control). Significant differences in Wnt target genes expression between IWP2 and vehicle 1012 
treated conditions were observed, *p-value<0.05 (t-test, two-tailed). Graph shows mean±SD 1013 
of 2 independent experiments. 1014 
 1015 
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Supplementary Figure 6: Transplantation of PLC tumouroids in immunodeficient mice.  1017 
(a) CC-2 and CC-3 tumouroids expanded for at least >3 months in culture were transplanted 1018 
subcutaneously (posterior flanks) on immunocompromised NSG mice and analysed for the 1019 
presence of tumour growth. Table summarizing the number of cells, site of engraftment and 1020 
analysis of tumour in the different mice. (b-c) Representative images of tumouroids 1021 
transplanted (b) under the skin (SC) or (c) under the kidney capsule (Kid.Cap.) of 1022 
immunodeficient mice. Scale bar, 2 mm. (d) Representative H&E staining of CC-2 1023 
tumouroids transplanted subcutaneously (SC) into NSG mice and corresponding CC-2 1024 
patient’s tumour tissue (bottom). Scale bars, 125µm (black), 62.5µm (inset). (e) Ki67 staining 1025 
on xenografts developed under skin (SC) revealed that the tumours were highly proliferative. 1026 
Scale bar, 125µm (top), 62.5µm (magnification). Similar data was obtained on xenografts 1027 
developed under kidney capsule (data not shown). (f) Lung metastasis were found on mice 1028 
transplanted with CC-1 tumouroids under the kidney capsule. Scale bar, 2mm. Magnification 1029 
2x. (g-h) Tumouroids were re-derived and expanded from tumours derived from CC-1 1030 
tumouroids transplanted into the kidney capsule (Kid.Cap.) or HCC-1 tumouroids 1031 
transplanted subcutaneously (SC) into immunocompromised NSG mice. (g) Representative 1032 
brightfield and H&E staining images obtained after 5 passages in culture. Scale bar, 500µm 1033 
(brightfield, top left), 200µm (brightfield, top right) and 125µm (H&E staining). (h) Ploidy 1034 
analysis of CC-1 and HCC-1 tumouroids rederived from xenografted tumours. Number of 1035 
metaphases counted, CC-1_O_Kid.Cap.#1, n=15; CC-1_O_Kid.Cap.#2, n=16, HCC-1036 
1_O_SC#1, n= 12. Experiment was performed at least in duplicate. Note that morphology, 1037 
histology and chromosome counts are maintained when comparing the parental tumouroids 1038 
(derived directly from patient’s tumour) and the tumouroids rederived after xenografting. 1039 
 1040 
Supplemental Figure 7: PLC tumouroid lines can be used to identify gene-drug 1041 
associations that may facilitate personalized therapy. 1042 
(a) Scatterplot of area under the dose-response curve (AUC) values obtained for the drugs 1043 
that were used to validate the drug screening using the tumouroid formation assay presented 1044 
in Fig.6d (Gemcitabine, Taselisib, Dasatinib, AZD8931 and SCH772984). Plots show the 1045 
correlation between the two biological replicates for each tumouroid line and each data point 1046 
represents the area under the dose-response curve (1-AUC) value. Red, sensitive. Triangle, 1047 
result further validated in the tumouroid formation assay. (b) Organoid cultures derived from 1048 
Healthy-1, HCC-1 and CC-1 tissues were tested for their sensitivity to treatment with the 1049 
EGFR inhibitor Gefitinib (1μM). Representative brightfield microscopy images (1 out of 2 1050 
independent experiments). Note that, CC-1 organoids were resistant to the treatment, while 1051 
Healthy-1 and HCC-1 organoids were sensitive, in agreement with their mutation profile (see 1052 
Fig. 4). Scale bars, 500μm and 100μm (insets). (c) GSEA analyses comparing tumouroid’s 1053 
and tissue’s gene expression signatures to 159 curated gene-sets associated with liver cancer 1054 
and stem cell. Representative GSEA plots obtained for a gene-set describing genes 1055 
overexpressed upon TGFB1 treatment (Coulouarn et al., 2008) and significantly upregulated 1056 
(FDR<25%, pvalue<0.05) in CC-2 patient’s tumouroid line and original tissue. +, 1057 
significantly upregulated. (d) In vivo activity of SCH772984 in HCC-1_O tumouroids grafted 1058 
under the skin of NSG mice. Mice were treated with drug/vehicle twice daily for 15 days 1059 
(n=3 in 2mg/kg of SCH772984 group, n=2 in vehicle group). Significant differences between 1060 
the SCH772984 and the vehicle treated groups were observed. *, p-value<0.01 and **, p-1061 
value<0.002 (t-test, two-tailed). Results are shown as percentage of the tumour volume 1062 
relative to day 0 (mean ±SD). (e) Histological analysis of the antitumour efficacy of 1063 
SCH772984 on HCC-1_O tumours. Representative H&E stainings on tissue sections from 1064 
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HCC-1_O tumours treated with either vehicle (left) or SCH772984 (right). Representative 1065 
images of 2 independent experiments are shown. Scale bar, 125uM. (f-g) Western blot 1066 
analysis for phosphorylated ERK1/2 (P-ERK) and total ERK (ERK) in either (f) tumouroids 1067 
in culture or (g) CC-1 xenografted tumours. (f) HCC1 and CC-1 tumouroid line ( _O) were 1068 
treated for 24 hours with either the pan-ERBB inhibitor AZD8931, the pERK inhibitor 1069 
SCH772984 or with the vehicle and samples were collected for western blot analyses as 1070 
described in methods. AZD8931 reduced ERK phosphorylation in HCC-1_O line only, 1071 
whereas SCH772984 potently inhibited ERK phosphorylation in both HCC-1_O and CC-1_O 1072 
lines, as expected according to their mutational profile (HCC-1_O, KRAS WT and CC-1_O, 1073 
KRAS G12D; see Figure 4). Representative blots of 2 independent experiments are shown. 1074 
(g) Target engagement of SCH772984 on phosphorylated ERK in CC-1 tumours grafted 1075 
under the skin of NSG mice. Tumours were dissected 6 hours after injecting SCH772984 1076 
(2mg/kg) or vehicle intratumourally. Homogeneates from these were obtained as described in 1077 
methods and probed to assess phosphorylated ERK1/2 (P-ERK) and total ERK (ERK) levels. 1078 
Representative blots of 2 independent experiments are shown. 1079 
 1080 
Supplementary Table 1: Patients’ information and organoid efficiency derivation and 1081 
expansion. 1082 
Table summarizing all the patient’s and healthy donor information including gender, age, type 1083 
of tissue, histological analysis, Ki67 index and serum AFP levels. Organoid growth and 1084 
expansion are indicated when appropriate. Efficiency of derivation and efficiency of organoid 1085 
expansion are calculated. Note that all healthy tissues derived from healthy donors 1086 
undergoing liver transplantation. N/A, not applicable; N/T, not tested. 1087 
*Organoids from HCC-NL1 patient (derived at Erasmus Rotterdam Centre) became 1088 
contaminated after some weeks in culture, and therefore were excluded from the analysis 1089 
 1090 
Supplementary Dataset 1: RNAseq data analysis. 1091 
Dataset including S1-S7 tables summarizing all the RNAseq data analyses except GSEA (see 1092 
Suppl. Dataset 2 and 3) and the TCGA analysis. Used for Fig.3. 1093 
Supplementary Dataset 2: Tumouroids GSEA data. 1094 
Dataset including S1-S15 tables summarizing the tumouroids GSEA data used for Fig. 3 and 1095 
Suppl. Fig. 4, 5 and 7. 1096 
Supplementary Dataset 3: Tissue GSEA data. 1097 
Dataset including S1-S15 tables summarizing the tissues GSEA data used for Fig. 3 and 1098 
Suppl. Fig. 4, 5 and 7. 1099 
Supplementary Dataset 4: WES. 1100 
Dataset including S0-S8 tables summarizing the cancer-related variants found in short (early) 1101 
and long (late) term expanded cultures and corresponding tissues used for Fig. 4g. 1102 
Supplementary Dataset 5: Drug screening.  1103 
Dataset including S1-S2 tables summarizing the List of drugs screened, their concentration 1104 
and the data used for Fig. 6 and Suppl. Fig. 7 1105 
Supplementary Dataset 6: List of antibodies, kits, and primers used. List of drugs 1106 
screened. 1107 
  1108 
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METHODS  1109 
Human specimens 1110 
Liver tumour biopsies (~1cm3) were obtained from biopsies or resection performed at 1111 
Erasmus Medical Center Rotterdam MEC-2013-143, Cambridge University Hospitals NHS 1112 
Trust REC: 15/LO/0753 (Approval by NRES Committee London – Westminster) and The 1113 
Royal Infirmary Hospital Edinburgh REC: 15/ES/0097. Healthy livers biopsies (~1cm3) were 1114 
obtained during liver transplantation performed at the Erasmus Medical Center, Rotterdam 1115 
MEC-2014-060 and at the Cambridge University Hospitals NHS Trust REC: 15/EE/0152. 1116 
The Cambridge samples were provided by the Cambridge Bioepository for Translational 1117 
Medicine (CBTM). All patients provided informed consent. Samples were procured and the 1118 
study was conducted under Institutional Review Board approval prior to tissue acquisition. 1119 
Samples were confirmed to be tumour or normal based on histopathological assessment. The 1120 
diagnosis of each case was confirmed on routine hematoxylin and eosin-stained slides by an 1121 
independent histopathologist. 1122 
Isolation and Culture of human liver healthy and tumoural organoids 1123 
Healthy liver-derived were isolated and cultured using our previously described method [23, 1124 
24] while tumour-derived organoids (tumouroids) were isolated by adapting this method as 1125 
follows. Tissue (~1cm3) was minced and incubated at 37°C with the digestion solution for 2-3 1126 
hours to overnight (O/N) according to the degree of liver fibrosis in the liver biopsy. The 1127 
digestion was stopped once no pieces of tissue were left, and the suspension was then filtered 1128 
through a 100µm nylon cell strainer and spun 5 min at 300-400G. The pellet was washed in 1129 
cold Advanced DMEM/F12 (GIBCO) then mixed with BME (Basement Membrane Extract, 1130 
Type 2, Pathclear). 10,000-30,000 cells were seeded per well in a 24-multi-well plate. After 1131 
BME had solidified, half of the wells obtained for each sample was cultured in the classical 1132 
human liver organoid isolation medium (Advanced DMEM/F12 supplemented with 1% 1133 
Penicillin/Streptomycin, 1% Glutamax, 10 mM HEPES, 1:50 B27 supplement (without 1134 
Vitamin A), 1:100 N2 supplement, 1.25mM n-Acetylcysteine, 10% (vol/vol) Rspondin-1 1135 
conditioned medium, 30% (vol/vol) Wnt conditioned medium, 10mM nicotinamide, 10nM 1136 
recombinant human [Leu15]-Gastrin I, 50ng/ml recombinant human EGF, 100ng/ml 1137 
recombinant human FGF10, 25ng/ml recombinant human HGF, 10μM Forskolin, 5μM A83-1138 
01, 25ng/ml Noggin and 10 μM Y27632 as described in [23, 24]). The other half was cultured 1139 
in a tumouroid specific isolation medium (classical human liver organoid isolation medium 1140 
(see above) without Noggin and Rspo1 and Wnt conditioned media but supplemented with 1141 
3nM Dexamethasone (Sigma Aldrich)). These media were kept until the first split (2-3 weeks 1142 
after isolation) then, changed into a classical human complete medium (Advanced 1143 
DMEM/F12 supplemented with 1% Penicillin/Streptomycin, 1% Glutamax, 10 mM HEPES, 1144 
1:50 B27 supplement (without Vitamin A), 1:100 N2 supplement, 1.25mM n-Acetylcysteine, 1145 
10% (vol/vol) Rspondin-1 conditioned medium, 10mM nicotinamide, 10nM recombinant 1146 
human [Leu15]-Gastrin I, 50ng/ml recombinant human EGF, 100ng/ml recombinant human 1147 
FGF10, 25ng/ml recombinant human HGF, 10μM Forskolin and 5μM A83-01 as described in 1148 
[23, 24]). Medium was changed twice a week. For tumouroid culture establishment, after 2-3 1149 
weeks in culture (depending on the sample) the growing structures were visually inspected 1150 
and, if required, contaminating healthy organoids were hand-picked to prevent these from 1151 
outgrowing the tumouroid structures. Upon attainment of dense culture, passaging was 1152 
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performed by mechanical dissociation into small fragments via trituration with a glass Pasteur 1153 
pipet, and transferred to fresh matrix in complete medium (composition described above). 1154 
To prepare frozen stocks, organoid cultures were dissociated and mixed with recovery cell 1155 
culture freezing medium (GIBCO) and frozen following standard procedures. When required, 1156 
the cultures were thawed using standard thawing procedures and cultured as described above. 1157 
For the 3-4 days (organoids) or first 2 weeks (tumouroids) after thawing, the culture medium 1158 
was supplemented with Y-27632 (10μM). Organoid pictures were taken with either a Leica 1159 
M80 stereoscope and Leica MC170 HD camera or with an inverted microscope Leica DMIL 1160 
and Leica DFC 450C camera. 1161 
Histology and staining 1162 
Tissues and organoids were fixed for 24 or 0,5 hours respectively, in 10% neutral buffered 1163 
formalin (Sigma), at room temperature, and then embedded in paraffin as follows: briefly, 1164 
tissues were processed through a graded ethanol series followed by xylene, and then 1165 
embedded in paraffin, cut at 5μm and stained (H&E and immunohistological staining). For 1166 
immunofluorescence experiments fixed organoids were rehydrated with PBS following 1167 
formalin fixation. For immunohistological staining, paraffin slides were deparaffinised and 1168 
subjected to antigen retrieval using citrate sodium solution pH=6. To reduce background 1169 
nonspecific staining, and permeabilise the sample, slides were incubated with a 3% BSA, 1170 
0,5% Triton in TBS solution for 1 hour. Primary antibodies (listed in the Suppl. Dataset 6_S1) 1171 
were then applied at appropriate dilutions for overnight at 4°C (see Suppl. Dataset 6_S1 for 1172 
details). Endogenous peroxidase activity was blocked for 15 min in a 3% hydrogen 1173 
peroxide/methanol buffer. Detection of bound antibody was accomplished with the 1174 
BrightVision Ultimate kit (Immunologic). Briefly, slides were washed in TBS and incubated 1175 
with a secondary antibody-HRP conjugate for 1hour at room temperature and finally 1176 
developed with 3,3′-diaminobenzidine (DAB) for 5 min, counterstained with hematoxylin, 1177 
and mounted with DPX (Sigma). Slides were also stained in the absence of primary 1178 
antibodies to evaluate nonspecific secondary antibody reactions. For TUNEL assay, Click-iT 1179 
Plus TUNEL kit (Molecular Probes, Life technologies) was used in accordance with the 1180 
manufacturer’s instructions. Pictures were taken with a Leica microscope DM 4000 1181 
microscope and DFC 450 camera (Leica). For whole mount immunofluorescence staining, 1182 
organoids were processed as described in [22, 23] [24]. Briefly, organoids were incubated 1183 
over 2 to 3 night at 4°C, washed in PBS, and revealed by incubation with a secondary 1184 
antibody conjugated to a fluorophore. Nuclei were stained with Hoechst33342 (Molecular 1185 
Probes, Life technologies). Confocal images were captured on a Leica SP5 inverted confocal 1186 
microscope (Leica). 1187 
Ki67 index 1188 
Each tumour slide stained for Ki67 was manually scanned with a microscope at × 10 1189 
objective, and the area of greatest Ki67 positivity (hot spot) was selected for photographing. 1190 
At least 1000 total tumoural cells were counted on a total of 2 independently stained slides 1191 
per patient. Pictures were taken with a Leica microscope DM 4000 microscope and DFC 450 1192 
camera (Leica) and Ki67-negative and -positive were then counted using ImageJ “cell 1193 
counter” plugin. Light brown or pale staining nuclei were ignored during counting. 1194 
Karyotyping 1195 
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Karyotyping was performed as previously described [23]. Briefly, cultures were incubated 1196 
with 0.1ug/ml Karyomax Colcemid (Gibco). After 24 hours, organoids were harvested and 1197 
dissociated using TrypLE (Gibco). Cells were incubated with KCL 0.0075M hypotonic 1198 
solution for 10 min, fixed in methanol:acetic acid (3:1) and dropped on a microscope slide for 1199 
visualization. Nuclei were mounted and stained using Vectashield with DAPI (Vector Labs). 1200 
A minimum of 15 metaphases per sample were counted. 1201 
Sequencing and analysis  1202 
For both RNA-Sequencing (RNASeq) and Whole-Exome Sequencing (WES), low quality 1203 
reads were filtered (<Q20) followed by trimming of low quality bases from the ends of the 1204 
reads (<Q20). Adaptors were also removed using cutadapt. 1205 
RNA-Sequencing. RNA was isolated from organoids using RNeasy mini kit (Qiagen) 1206 
following manufacturer's instructions. RNA libraries were prepared for sequencing using the 1207 
Smartseq2 method. RNA sequencing was performed using Illumina HiSeq sequencer (50bp 1208 
single-end reads and 10-20 million reads were generated for each sample). Reads were 1209 
aligned with Tophat (v2.1.0) [67] to the GRCh38.82 genome, using the corresponding gtf file 1210 
for exon positions. Counts were generated using featureCounts (v1.5.0-p1) [68]. Only 1211 
protein-coding genes, lincRNAs, processed transcripts and misc RNA were kept for further 1212 
study. Normalised counts were created using DESeq2 [69] and RPKMs using edgeR's 1213 
function [edgeR]. The technical and biological replicates were merged. To assess 1214 
concordance of tissues with organoids genes were filtered and the Pearson’s correlation 1215 
coefficient was calculated pairwise between tissues and organoids. The correlation matrix was 1216 
then z-scored. The principal components for several subgroups of the samples were calculated 1217 
from the normalised DESeq counts, and the first two (PC1, PC2) were plotted. We then 1218 
analysed the top 100 genes with highest loadings across PC2, which separated the samples by 1219 
subtype. Functional analysis was split across the three subtypes, and genes were excluded in 1220 
each unless healthy or tumour samples had RPKM values greater than 1. To generate a 1221 
statistic for tumoural tissue samples, the log2 fold change (FC) of each tumoural tissue was 1222 
divided by the mean of the healthy tissues. To generate a statistic for HCC tumouroid 1223 
samples, two log2 fold changes (FC) were calculated: the first was HCC organoid divided by 1224 
the mean of healthy liver-derived organoid and the second was HCC tissue divided by the 1225 
mean of the healthy tissues. Then the mean or minimum was then taken of these two ratios, 1226 
whichever had a lower absolute value. The same statistic was generated for CHC and CC 1227 
tumouroids using the mean healthy tissue instead of healthy liver-derived organoid as a 1228 
baseline for the first fold change. These statistics were then used for pre-ranked gene set 1229 
enrichment analysis using GSEA software (http://www.broadinstitute.org/gsea/) [70]. 159 1230 
gene sets were used for running the GSEA. These gene sets were obtained after curation of 1231 
the publically available C2 MSigDB collection for “LIV”, “HEPT” and “STEM” key words 1232 
and completed by available liver cancer gene set described in literature (see Supplementary 1233 
Dataset 2 and 3) in order to select a relevant list of gene sets associated with liver cancer and 1234 
stemness. 1,000 permutations were used to calculate p-value. A tumouroid signature was 1235 
identified by finding genes with the highest FC when dividing the minimum expression value, 1236 
in RPKMs, over all tumouroid samples by the mean of the expression of healthy liver-derived 1237 
organoids in differentiation medium. Several aspects of the genes defining the tumouroids' 1238 
signatures were annotated: the description of their corresponding proteins was downloaded 1239 
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from Uniprot [71], and their relevance to disease by retrieving the Disease Ontology terms 1240 
(using the R package dnet v1.0.10 [72]).  1241 
WES. DNA from tumour tissue and matched tumouroid lines was extracted using DNeasy 1242 
Blood & Tissue Kit (Qiagen) according to manufacturers' protocol. Somatic point mutations 1243 
and short indels were called in a procedure composed of several steps as follows: (i) Reads 1244 
were aligned to the UCSC hg38 genome using Bowtie2 (v2.2.6) [73] and the output was 1245 
preprocessed for variant calling by marking duplicates with Picard (v1.113) 1246 
(http://broadinstitute.github.io/picard/) followed by Indel realignment with the GATK toolkit 1247 
(v3.7) [74]. SNPs and Indels were called with Varscan (v.2.3) [75]. (ii) We identified and 1248 
selected the variants with the following parameters: base quality ≥15 (Phred score), read 1249 
depth ≥15 and annotated by SNPEff [76] as not “intergenic”. (iii) We removed SNPs on 1250 
alternate haplotypes. (iv) Analysis was then split between patients. For each, there were 3 1251 
samples, the tissue and the corresponding tumouroids expanded for <2months (early) or 1252 
>4months (late). If a SNV was called in the ‘early’ sample, a SNV was added in the tissue if 1253 
its pileup showed evidence of the same variant at that position. Moreover if a SNV was called 1254 
in the ‘late’ sample, a SNV was added in the tissue and early sample if their pileup both 1255 
showed evidence of the same variant at that position. Figure 4c-e and Suppl. Figure 5a are 1256 
based on this final list of somatic variants. To assess concordance, overlaps of SNVs found in 1257 
tissue and early and late tumouroids were calculated within and between cancer types using 1258 
GATK (v3.7). The mutation spectrum was examined in each sample in both non-transcribed 1259 
and transcribed strands and then summarized by representing the average proportion across 1260 
all samples. A cancer related set of variants was defined by adding the following filtering 1261 
steps: (v) SNVs which were included in dbSNP (v150) [77] were excluded, with the 1262 
exception of those which were also included in COSMIC (v76) [78]. The variant positions 1263 
with their associated effects were annotated with SnpEff. Figure 4f is based on this final list 1264 
of somatic variants. A summary of the concordant (tissue/early/late) variants obtained per 1265 
patient is provided in Suppl. Figure 5b. (vi) Synonymous SNVs were filtered out as were 1266 
assumed to be unlikely involved in cancer. (vii) A final filtering step was performed selecting 1267 
for variants present in a panel of genes created based on literature (847 genes described in 1268 
cancer). Resultant variants are provided in Suppl. dataset 4 and were used to find relevant 1269 
mutations described in Figure 5g. 1270 
Accession Numbers 1271 
All RNA-seq and WES data are available at Gene Expression Omnibus (GEO) under 1272 
accession number GSE84073.  1273 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84073 1274 
The Cancer Genome Atlas (TCGA) analyses 1275 
We examined the expression of the top 30 genes of this tumouroid signature, in public 1276 
available data generated by the TCGA Research Network: http://cancergenome.nih.gov/. 1277 
FPKMs were downloaded from The Genomic Data Commons Data Portal (GDC), using 1278 
GDC’s API, for the projects TCGA-LIHC (374 tumoral samples (ICD-O-3 number=C22.0) 1279 
and 50 normal control samples) and TCGA-CHOL (31 tumoral samples (ICD-O-3 1280 
number=C22.1) and 8 normal control samples). From the FPKM values of tumoral and 1281 
control samples we generated base R boxplots and assess the significance between both group 1282 
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by unpaired two-tailed t-test. Survival plots were created using the R package TCGAbiolinks 1283 
(v2.2.10) [79] and by splitting, per gene, the tumour samples into high- and low-expression 1284 
groups. The median of all samples was used as the threshold and significance for differences 1285 
between the two groups was assessed by log-rank test. 1286 
Quantitative RT-PCR 1287 
Total RNA was extracted from organoid cultures or freshly isolated tissues using RNeasy 1288 
mini kit (Qiagen) in accordance with the manufacturer’s instructions. cDNA was synthesized 1289 
using 0.5μg of total RNA and a M-MLV Reverse Transcriptase kit (Promega). cDNA was 1290 
amplified with iTaq™ Universal SYBR Green Supermix (BioRad) and using gene-specific 1291 
primers described in Suppl. Dataset 6_S3). All targets were amplified (40 cycles) on a CFX96 1292 
Touch Real-Time PCR Detection System (Biorad). Data were analyzed using BioRad CFX 1293 
manager. Expression levels were normalized to the expression of the housekeeping gene 1294 
HPRT. 1295 
Functional in vitro studies 1296 
Functional studies were performed in collected supernatant or in whole organoids. To assess 1297 
albumin production, culture medium was collected 1 week after the last medium change and 1298 
albumin levels were assessed using an Albumin ELISA kit (Assay Pro) according to 1299 
manufacturer’s instructions. Values were corrected for time and cell number. Concentration 1300 
of total bile acid was established using a Total Bile Assay kit (Cell Biolabs, inc.) according to 1301 
manufacturer’s instructions on supernatant obtained after sonication of whole organoids in 1302 
PBS. 1303 
Organoid formation Assay 1304 
To assess the organoid formation efficiency in classical vs tumouroid isolation medium, 1305 
pictures of all full drops of BME obtained per patient were photographed using a Leica M80 1306 
stereoscope 2-3 weeks after isolation (depending on the sample) and all viable tumouroid 1307 
structures were counted. 1308 
For the drug sensitivity assays, organoids were dissociated into 2-5 cell clumps by enzymatic 1309 
dissociation with TrypLE (Life Technologies). Then, cell viability assays were conducted by 1310 
plating 500 clumps per well of a 48-well cell culture plate in 250μl of complete human 1311 
medium supplemented with 0.5 μM Gemcitabine (Actavis), or 5 μM of AZD8931 1312 
(Selleckchem), or 10μM of SCH772984 (Selleckchem) or 2μM Dasatinib (Selleckchem) or 1313 
10μM of Taselisib (Selleckchem) or 3μM of IWP2 (Sigma Aldrich) or 1μM of Gefitinib 1314 
(Selleckchem) or vehicle (DMSO) control. All conditions were supplemented with Rho 1315 
kinase inhibitor Y-27632 (Sigma-Aldrich). The concentration selected for each compound 1316 
was based on the cell viability data from our laboratory, the results from the screening or the 1317 
literature. Medium was changed 3 times a week for 3 weeks. Viable cells were assessed by 1318 
their ability to generate organoid de novo. Representative pictures of the viability result were 1319 
taken 2-3 weeks after starting the treatment. All cell viability experiments were conducted at 1320 
least in duplicate. 1321 
Drug screening 1322 
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Organoid viability assays were conducted as previously described [18, 60]. Briefly, 8µl of 1323 
~7mg/ml BME-2 was dispensed in to 384-well microplates and allowed to polymerize. 1324 
Organoids were mechanically dissociated by pipetting before being resuspended in 2% 1325 
matrigel/growth media (15,000-20,000 organoids/ml) and dispensed into 384-well plates. The 1326 
following day a 7-point half-log dilution series of each compound was dispensed using liquid 1327 
handling robotics and cell viability assayed using CellTiter-Glo® (Promega) following 6 days 1328 
of drug incubation. Screens were performed in technical (same screening run) and biological 1329 
duplicates, and all screening plates were subjected to stringent quality control measures and a 1330 
Z-factor score comparing negative and positive control wells was calculated. Dose–response 1331 
curves were fitted to the luminescent signal intensities utilizing a method previously 1332 
described [80]. Variation in replicates was greater than similar screens performed in 1333 
colorectal tumouroids and was likely due to the large size of HCC tumouroids leading to 1334 
uneven distribution in screening wells [18, 60]. Compound and screening concentrations are 1335 
provided in Supplementary Dataset 5_S1. The range of concentrations selected for each 1336 
compound was based on in vitro data of concentrations inhibiting relevant target activity and 1337 
cell viability based on data from our laboratory or literature. 1338 
Mouse xenograft studies 1339 
All mouse experiments have been regulated under the Animals (Scientific Procedures) Act 1340 
1986 Amendment Regulations 2012 following ethical review by the University of Cambridge 1341 
Animal Welfare and Ethical Review Body (AWERB). For subcutaneous grafts, 1 million 1342 
cells suspensions were prepared in PBS-0.1%BSA (CC and healthy liver-derived organoid 1343 
lines) or in Advanced DMEM/F12 (GIBCO) 1% glycosil (ESI-BIO) further supplemented 1344 
with 50 ng/ml each of HGF and VEGF (HCC and healthy liver-derived organoid lines) and 1345 
were injected into both flanks of male NSG-NOD scid gamma mice (Charles River). Visible 1346 
tumours developed in approximately 2–4 weeks (CC organoid lines) and 4-6 months (HCC-1 1347 
organoid line). Mice were culled when the tumour reached limit end-point (size or 1348 
ulceration). For kidney capsule graft, cell line suspensions were prepared in Advanced 1349 
DMEM/F12 (GIBCO) with BME2 (7mg/ml) and 500,000 cells were implanted under the 1350 
renal capsule of NSG mice. These mice were then culled at different time point (0.5, 1, 2 and 1351 
3 month) and kidney and lung tissues were harvested to assess the growth and the metastatic 1352 
potential of the grafted cells.  1353 
To assess the efficiency of the ERK inhibitor SCH772984 in vivo mice with established 1354 
subcutaneous tumours were randomized to drug treatment by splitting size-matched tumours 1355 
in two groups (SCH772984/vehicle). Treatments (SCH772984 at 2 mg/kg, or an equal 1356 
volume of vehicle (25%DMSO-30%PEG300 in DD water)) were administered by 1357 
intratumoural injection twice daily for 15 (CC-1 tumouroid line) or 20 (HCC-1 tumouroid 1358 
line) days. Tumour sizes were measured 3 times a week after the first week of treatment using 1359 
a caliper and volumes were calculated by applying the formula v = 0.5 × L × w × h, where v 1360 
is volume, L is length, w is width and h is height. Investigators performing tumour 1361 
measurements were blinded to treatment groups.  1362 
Western blot assay 1363 
Cell lysate for Western blotting were prepared from tumouroids grown for 24 hours in 1364 
complete human medium supplemented with 10μM of SCH772984 (Selleckchem), or 5 μM 1365 
of AZD8931 (Selleckchem) or equal volume of vehicle (DMSO), then washed with ice-cold 1366 
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PBS to remove the basement matrix and from CC-1 xenografted tumours 6 hours after 1367 
intratumoural injection of 2mg/kg of SCH772984 (Selleckchem). Lysates were made in ice-1368 
cold buffer consisting of 50mM Tris-HCl (pH 7.4), 150mM NaCl, 2mM EDTA, 50mM NaF, 1369 
1% triton, 1% NP-40, 0.1% SDS, 0.5% Na-deoxycholate, supplemented with 1mM sodium 1370 
orthovanadate and protease inhibitor cocktail (Roche) (15min on ice for the cells and 30min 1371 
on ice for the tissues). Protein lysates were cleared by microcentrifugation at 10,000 rpm for 1372 
10 min at 4°C and the supernatants aliquoted and stored at −20°C. Equivalent amounts of 1373 
protein from each sample were separated on 10% SDS-PAGE gels and then transferred by 1374 
electroblotting onto nitrocellulose membranes. Membranes were then blocked in in PBS-0.1% 1375 
Tween-5% BSA and immunoblotted with the following antibodies overnight at 4°C: ERK 1376 
(1/2000), P-ERK (1/3000) (Cell signalling). After washing 3 times in PBS-0.1% Tween, the 1377 
membranes were incubated for 1h at room temperature with anti-rabbit horseradish 1378 
peroxidase (HRP)-conjugated secondary antibodies (1:10,000; abcam). Antibody-protein 1379 
complexes were visualised using ECL Prime Western Blotting Detection Reagent (GE 1380 
Healthcare). 1381 
Statistical Analyses 1382 
All summary data are presented as mean ± SD or representative images of at least 2 1383 
independent experiments. All statistical analyses were performed in R and GraphPad Prism 1384 
software (GraphPad 7.0). Sample size (n) values used for statistical analyses are provided in 1385 
the relevant figures and supplementary figures. Tests for differences between two groups 1386 
were performed using Mann-Whitney’s two-tailed test, Student's two-tailed unpaired t-test or 1387 
log-rank test as specified in the figure legends. When using t-test we assumed normality and 1388 
equal distribution of variance between the different groups. No data points were excluded 1389 
from the statistical analyses. Significance was set at FDR ≤ 0.25 (for GSEA) and p-value ≤ 1390 
0,05 (for all other experiments).  1391 
 1392 
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Figure 1: Patient-derived primary liver cancer organoid cultures expand long-term in vitro while preserving the histological 
architecture of the specific subtype of primary liver tumour they derived from. 
(a) Experimental design. For each tissue, samples were split into 4 parts and processed for histology, RNA and DNA isolation, or 
dissociated and processed for organoid culture. Healthy (donor-derived) liver tissues, moderate/well differentiated hepatocellular 
carcinoma (HCC), combined hepatocellular-cholangiocarcinoma (CHC) and cholangiocarcinoma samples (CC) were obtained from 
patients undergoing surgery (patient’s information detailed in Supplementary Table 1) and were processed as described in Methods 
and Suppl. Fig.1. (b) Representative H&E staining of healthy liver tissue and primary tumour (top row), and corresponding brightfield 
microscopy images (middle row) and H&E histological analysis of the organoid lines derived from these (bottom row). Note that, while 
healthy liver-derived organoids (left) grew as single layered epithelium of ductal-like cells surrounding a central lumen (*, duct; L, 
lumen), tumour-derived organoids (= tumouroids) formed solid/compacted structures that resembled the corresponding tumour-of-ori-
gin [compare tissue (top row) with the corresponding organoid histology (bottom row)]. HCC-1 tumouroids exhibit pseudoglandular 
rosettes (arrowheads, bottom row), a hallmark of HCC, also found in the parent tumour tissue (arrowheads, top row). CC-1 
tumouroids, present a glandular lumen, similar to the original patient’s tumour (top row). Scale bars, middle rows 100µm; top and 
bottom rows, 50µm. Brightfield and H&E pictures from other lines are provided in Suppl. Fig. 2. (c) Organoid formation efficiency in 
classical human healthy liver isolation medium (see Broutier et al, 2016 for details) and tumouroid specific isolation medium (classical 
human healthy liver complete medium without RSPO + 3nM Dexamethasone - see Methods and Suppl. Fig1 for details). Graph repre-
sents mean±SD of the total number of tumouroids obtained per well of each condition. (d) Expansion potential of tumouroid cultures 
established and their correlation to the expansion of healthy-tissue derived organoids. Arrow, continuous expansion. Dot, passage.
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Figure 2: Immunohistochemistry analyses reveal that the PLC tumouroids retain expression patterns of the distinct 
subtype of the original tissue they derived from, even after long-term expansion in culture. 
(a) Schematic representation of the multiple subtypes among types of primary liver cancers (PLC). (b) IHC assays on the PLC 
tissues including hepatocyte/HCC marker (HepPar1) and ductal/CC marker (KRT19). Scale bar, 125 μm. Dashed red square 
indicates focal staining. (c) Immunofluorescent analysis for the HCC marker AFP (in red) and the ductal/CC marker EpCAM (in 
green), on tumouroids expanded in culture for at least 3 months. Nuclei were counterstained with Hoechst33342. Scale bar, 30µm.
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Figure 3: Genome wide gene expression analysis indicates that the tumouroids recapitulate the expression profile of the specific 
subtype of primary liver cancer (PLC) they were derived from and allow identifying potential new genes involved in PLC.
(a) Correlation heat map between PLC-tissue ( _T) and paired PLC-derived organoid line ( _O) expression profiles showing that the 
tumourigenic profile of the original tissue and specific subtype of PLC is maintained after long-term expansion in culture. Red, strong corre-
lation; blue, low correlation. (b) PCA analysis showing samples plotted in 2 dimensions using their projections onto the first two principal 
components (PC1 and PC2). Each data point represents one sample, dot stands for tumouroids lines, triangle for PLC tissues. PC1 is 
strongly correlated with the type of sample (tumouroids vs tissue) whereas PC2 defines the 3 different PLC subtypes (HCC, CHC and CC). 
Of note, tumouroid lines and tissues are distributed consistently along PC2 according to their own PLC subtype. Some genes from the top 
100 genes with highest loadings across PC2 are shown. (c) Heat map analysis of the log2 RPKM values (raw z-scored) of selected genes 
found highly expressed (red) in HCC and/or CHC and/or CC tumouroids. (d) Gene set enrichement analysis (GSEA) comparing the 
tumouroid lines’ and associated tissues’ gene expression signatures to 159 curated gene-sets associated with liver cancer and stem cell 
(representative plots shown in Suppl. Fig. 4). The heatmap shows some of the significantly UPregulated and DOWNregulated gene-sets 
(False discovery rate (FDR)<25%) in the tumouroid lines and paired tissues. Full list of gene-sets and significantly enriched gene-sets can 
be found in Suppl. dataset 2 and 3. (e) Schematic of the tumouroid signature. Venn diagram overlapping the upregulated genes in each 
tumouroid line compared to healthy organoids. (f) Table summarizing the results of the gene expression patterns (OE, overexpression) and 
outcome prediction (KM, Kaplan-Meier) analyses performed for the top genes of the tumouroid signature using publically available TCGA 
cohorts. The table details the p-values obtained for each analysis (OE in PLC, two-sided t-test ; KM analysis, log-rank test). p-value≤0.05 
are defined as significant and color coded using yellow in the table. Only top the 25 genes are represented (Top 30 genes analysis and 
corresponding values can be found in Suppl. dataset 1). TCGA-HCC, 374 tumoural /50 normal samples; TCGA-CC, 31 tumoural /8 normal 
samples. (g) Box plots for the expression of STMN1, C1QBP and C19orf48 in tumoural and normal tissues using the TCGA-HCC and/or 
CC cohorts. (h) Kaplan-Meier analyses in the TCGA-HCC and/or TCGA-CC cohorts based on the expression level of the gene of interest 
(STMN1, C1QBP and C19orf48) in the tumoural samples.
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Figure 4: Tumouroids recapitulate the genetic alterations present in the patient’s tumour. 
(a) Ploidy analysis of tumouroid cultures expanded for at least 2 months in culture. Results are expressed as % of ploidy per number 
of metaphases counted (at least 25 total). Healthy-derived organoids were used as control. Experiment was performed at least in 
duplicate. (b) Representative images of organoid metaphases used for the ploidy analysis. (c-g) All somatic variants identified in all 
samples (21 total; 7 patients with 3 samples (Tissue/early organoid/late organoid)) were used for the global analyses after filtering for 
quality control as detailed in methods (c-e). For f-g, an additional filtering step was applied: a cancer related set of variants was 
defined by adding the following filtering steps: (1) SNVs, which were included in dbSNP were excluded, with the exception of those 
which were also included in COSMIC database (resultant variants are detailed in Fig. 4f and Suppl. Fig. 5b). (2) Synonymous SNVs 
were filtered out as were assumed to be unlikely involved in cancer. (3) A last filtering step was performed selecting for variants 
present in a panel of genes described in literature to be involved in cancer (847 cancer related genes total, for details see Suppl. 
Dataset 4). Resultant variants are provided in Suppl. Dataset 4 and were used to select relevant mutations described in Figure 5g. 
(c) Correlation heat-map between PLC-tissues ( _T) and PLC-tumouroids ( _O) variants identified. (d) Proportions of somatic variants 
across the samples, the 6 types of SNVs and the indels are represented. (e) Percentage of the 6 types of SNVs averaged across all 
samples (21 total; 7 patients with 3 samples (Tissue/early organoid/late organoid samples)). Graph represents mean±SD. (f) Bar 
plots indicate the concordance between the cancer related somatic variants identified in the tumour-of-origin and the corresponding 
tumouroids expanded for short or long term in culture. (g) Genes altered in tumouroid cultures and associated tissues and known to 
be mutated in liver OR gastrointestinal tumours. The type of mutation is indicated in the legend. OxS, oxidative stress.
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Figure 5: PLC tumouroids recapitulate patient’s PLC tumour subtype and metastasis in vivo when transplanted in mice.
(a) Experimental design. PLC tumouroids or Healthy liver-derived organoids expanded for >3 months in culture were transplanted 
subcutaneously (SC) or under the kidney capsule (Kid.Cap.) of immunocompromised NSG mice and analysed for the presence of 
tumour growth and metastasis following grafting. (b-c) Tables summarizing the number of cells, site of engraftment and analysis of 
tumour and lung metastasis. No tumour lesions were found in any of the mice receiving Healthy-1 organoids. Tumours were 
dissected at 1 (CC-1_O and Healthy-1_O) and 5 (HCC-1_O and Healthy-1_O) months  (SC graft) and 0.5, 1, 2 and 3 months 
(Kid.Cap. graft) after injection. (d) Representative H&E staining of CC-1 tumouroids transplanted subcutaneously (top) into NSG 
mice and corresponding CC-1 patient’s tumour sample (bottom). Note that the grafted CC-1 tumouroids tissue (top) recapitulates 
the histo-architecture of the patient’s original tumour (bottom) including the extensive desmoplasia found on the CC-1 original 
sample (arrowheads). Scale bars, top left 250µm, top right 125µm, bottom left 125µm, and bottom right 62.5µm. (e) Representative 
H&E staining of HCC-1 tumouroids transplanted subcutaneously (top) into NSG mice and corresponding HCC-1 patient’s tumour 
sample (bottom). Note that the grafted HCC-1 tumouroids tissue (top) recapitulates the histo-architecture of the patient’s original 
tumour (bottom) including the pseudoglandullar rosettes, hallmark of HCC-1 original sample (dashed circle). Scale bars, left 
125µm, right 62.5µm. (f) Representative H&E (left) and KRT19 (right) immunohistochemistry analyses of CC-1 tumouroids trans-
planted under the kidney capsule of NSG mice. Scale bars, 125µm. (g) Lung metastases derived from the human CC-1 tumouroids 
transplanted under the kidney capsule cells (right panels) were identified using a human specific KRT19 antibody. No metastases 
were found in the lungs of mice transplanted with Healthy-1 organoids (left panels). Scale bars, 500µm, magnification 125µm.
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Figure 6
Figure 6: PLC tumouroid lines are a valuable resource for drug screening and allowed identification of ERK as a potential target for 
primary liver cancer.
(a) Scatterplot of 1-AUC values from two biological replicates of the drug screening data, highlighting drugs inducing a viability effect in five liver 
tumouroid lines. Each data point is the 1-AUC value for a given drug in a particular tumouroid line. (b) Dose-response curves after 6 days 
treatment with Gemcitabine, Nutlin-3a, LGK974 and SCH772984 generated from the luminescent signal intensities. Data displayed are average 
of the technical and biological replicates. (c) Summary of the different drugs used in the drug screening, the associated pathway and nominal 
targets and the screen results represented as a summary of the the 1-AUC and IC50 data generated for the different tumouroid lines. Red, IC50 
within the screen range; Dense dotted pattern, 1-AUC>0.15 and dose response; scattered dotted pattern, 1-AUC>0.15 and sensitivity at highest 
value only. Compounds highlighted in yellow were selected for further validation. (d) Validation of viability effects of a subset of compounds 
using an organoid formation assay (see details in methods). (e) In vivo activity of SCH772984 in CC-1_O tumouroids grafted under the skin of 
NSG mice. Mice were treated with drug/vehicle twice daily for 20 days (n=5 in 2mg/kg of SCH772984 group, n=8 in vehicle group). From day 
7 onwards, significant differences between the SCH772984 and the vehicle treated groups were observed. *, p-value<0.01; **, p-value<0.002 
(Mann Whitney test, two-tailed). Results are shown as percentage of the tumour volume relative to day 0 (mean ±SD). (f-g) Histological analysis 
of the antitumor efficacy of SCH772984 on CC-1_O tumors was assessed 24 days after starting the treatment. Representative (f) H&E and (g) 
TUNEL staining performed on tissue sections from CC-1_O tumours treated with either vehicle (left) or SCH772984 (right). Representative 
images from 2 independent experiments are shown. Scale bar, 125μM (H&E) and 25μM (TUNEL).
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